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Marburg virus (MARV)–along with Ebola Virus–comprises Filoviridae, a family of
virus which causes the life-threatening hemorrhagic fever in human and non-human pri-
mates for which there is no clinically approved vaccine. For this reason, this virus can
potentially lend itself to pandemic and weapons of bioterrorism. Strikingly, this virus
yields asymptomatic responses in its recently discovered host Rousettus aegyptiacus. Un-
derstanding of the interaction between MARV and different animal hosts will enable the
improved understanding of filovirus immunology and the development of effective thera-
peutic agents.
Although cell lines and primary cells have been used to investigate gene expression
analysis of this virus, the transcriptomic view of MARV infection on the tissue samples of
animal hosts has been an uncharted territory. The comprehensive analysis of transcriptome
in hosts and spillover hosts will shed light on the immune responses on a molecular level
and potentially allow the comparative analysis to understand the phenotypical differences.
However, there have been gaps in resources necessary to carry the transcriptome re-
search for MARV. For example, MARV host Rousettus aegyptiacus genome and transcrip-
tome had not been available. Furthermore, the statistical machinery necessary to analyze
multi-tissue/multi-time data was not available.
In this dissertation, I introduce the two items that fill these gaps and show the appli-
cation of the tools I built for novel biological discovery. In particular, I have built 1) the
comprehensive de novo transcriptome reference of Rousettus aegyptiacus and 2) the Mul-
tilevel Analysis of Gene Expression (MAGE) pipeline to analyze the RNA-seq data with
the complex experimental design.
I show the application of MAGE in multi-time, multi-tissue transcriptome data of
Macaca mulata infected with MARV. In this study, 15 rhesus macaques were sequentially
sacrificed via aerosol exposure to MARV Angola over the course of 9 days, and 3 types of
lymph node tissues (tracheobronchial, mesenteric, and inguinal) were extracted from each
sample and sequenced for gene expression analysis.
With MAGE pipeline, I discovered that the posterior median log2FC of genes sepa-
rates the samples based on day post infection and viral load. I discovered the set of genes
such as CD40LG and TMEM197 with interesting trends over time and how similar and
different pathways have been influenced in three lymph nodes. I also identified the bio-
logically meaningful clusters of genes based on the topology-based clustering algorithm
known as Mapper. Using the MAGE posterior samples, I also determined the genes that
are preferentially expressed in tracheobronchial lymph nodes. In addition to new analysis
tools and biological findings, I built the gene expression exploration tool for biologists to
examine differential gene expression over time in various immune-related pathways and
contributing members of the pathways.
In conclusion, I have contributed to the two important components in the transcriptome
analysis in MARV research and discovered novel biological insights. The MAGE pipeline
is modular and extensible and will be useful for the transcriptome research with the com-
plex experimental designs which are becoming increasingly prevalent with the decrease in
the cost of sequencing.
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Introduction
0.1 Motivation of this thesis
Marburg virus (MARV) belongs to the viral family Filoviridae that causes severe hemor-
rhagic fever disease in humans and nonhuman primates, but results in little to no patholog-
ical consequences in bats (Bean et al. 2013; Towner et al. 2006). Little has been done for
the comprehensive and global characterization of MARV pathogenesis in animal hosts due
to lack of the data and resources such as the genome and transcriptome of hosts.
The comprehensive analysis of transcriptome in hosts such as bats and spillover hosts
such as non-human primates will shed light on the characteristic immune responses due
to MARV infection on a molecular level and potentially allow the comparative analysis
to understand the phenotypical differences, ultimately increasing our understanding of this
virus and chances of developing effective treatments.
However, there have been gaps in resources necessary to carry the transcriptome re-
search for Marburg virus. For example, until recently, Marburg virus host Rousettus ae-
gyptiacus genome and transcriptome had not been available. Furthermore, the statistical
machinery available to analyze the RNA-seq data with complex experimental design were
limited.
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To this end, I worked toward bridging this gap in my doctorate program, especially
in the space of transcriptomic analysis. I have built the comprehensive de novo transcrip-
tome reference of Rousettus aegyptiacus and the Multilevel Analysis of Gene Expression
(MAGE) framework designed to handle the complex RNA-seq experiments with more than
one factor.
Before diving into the detailed contents of my thesis in each chapters that follow, let
me briefly discuss the history of gene expression analysis, which will lay the foundation
for everything that follows.
0.2 History of Gene Expression Analysis and High
Throughput Transcriptome Analysis
All organisms–according to the famous cell theory by Theodor Schwann and Matthias
Jakob Schleiden (Wikipedia 2004)–consist of one or more cells, which themselves consist
of multiple entities. Therefore, to understand any organism, one must study the processes
of its cells and the constituents involved, in particular what they are and how they do what
they do. In the field of molecular biology, one such activity is the quantification of the
expression of a gene, also known as gene expression analysis.
Accurate quantification of expressions of individual genes under the particular state of
cells is a key to understanding the role of genes in physiology, pathology, and immunology
of an organism (Barczak et al. 2012; Liang and Pardee 1992). With the relevant genes quan-
tified, one can perform differential gene expression analysis measuring the change of gene
2
expression as a function of multiple biological states to infer the molecular mechanisms of
biological functions and regulations as well as to predict clinical outcomes.
As the techniques and methodologies of molecular biology become more sophisti-
cated and advanced, the researchers became increasingly interested in quantifying mul-
tiple genes simultaneously–also known as gene expression profile. Hence, the analysis of
transcriptome–a set of all RNA transcripts–has become increasingly popular. There was a
huge interest in transcriptomic analysis because by studying expressions of multiple genes
together, one can obtain the holistic and systematic view of a particular state,whether it be
normal, cancerous, or disease, in cell populations. Furthermore, it can speed up the dis-
covery for the determinants of particular biological states and targets for interventions (Ye
et al. 2002).
In early 90s, gene expression of multiple genes was measured by the technologies such
as differential display (Liang and Pardee 1992), expressed sequence tags (EST) (Adams
et al. 1991), and Serial Analysis of Gene Expression (Velculescu et al. 1995). Between the
mid 90s and early 2000s, it was widely performed with microarrays (Brazma et al. 2001;
Duggan et al. 1999; Pan 2002; Schena et al. 1995; Van’t Veer et al. 2002; Watson et al.
1998). Since thousands of genes were measured simultaneously, the need for Bioinfor-
matics has increased as well. Many statistical tools have been developed to address the
challenges that come with how the data were generated (more on this in the next section
). Although microarrays are useful, they also have limitations; one prominent issue was
that it could only quantify known genes since it relied on hybridization techniques and this
issue is problematic for genes with complicated splicing schema and unknown structure
(Mortazavi et al. 2008).
3
Since the mid 2016, however, the RNA-seq analysis become the de facto method to an-
alyze gene expression simultaneously (Mortazavi et al. 2008; Wang, Gerstein, and Snyder
2009). It enabled the high-throughput digital quantification at a single nucleotide level in an
accurate way. Compared to microarray, RNA-seq offers higher sensitivity and specificity:
It could not only quantify previously unknown genes, did not have cross-hybridization
and background normalization issues, and has high correlations among technical replicates
(Mortazavi et al. 2008; Wang, Gerstein, and Snyder 2009).
Despite the ease of ability to quantify the global gene expression with the the help of
microarray or RNA-seq, it comes with another set of challenges. The data generated from
high-throughput sequencing technology is stochastic, and this resulted in the development
of various normalization techniques and statistical models. Normalization techniques such
as quantile normalization, TMM-normalization, and DESeq normalization have been de-
veloped to mitigate the biases that might be caused by differences in library sizes and gene
expression composition (Bolstad et al. 2003; Degexp et al. 2010; Oshlack, Robinson, and
Young 2010). Another issue is the statistical modeling of the underlying error model based
on a platform. For example, with microarray, the unit of measurements is the light in-
tensity (real values) whereas in RNA-seq the data were generated in the form of counts.
The former is usually modeled with normal distribution, and the latter Poisson or nega-
tive binomial distribution. More importantly, despite that the measurements were done for
thousands of genes, the number of experimental units were usually limited to three due
to the cost. The small number of replicates posed yet another problems; naively applying
the traditional statistical tools such as t-test would lead to exaggerated parameter estimates
and result in high false positive results. To address this issues, the tools such as limma,
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edgeR, or DESeq (Degexp et al. 2010; Robinson, McCarthy, and Smyth 2010a; Smyth
2005) have been developed to leverage information sharing across genes with similar gene
expression level. With these tools, numerous novel and important biological discoveries
are continually being made at an increasing speed.
0.3 Gene Expression Analysis Workflow
Figure 0.1: Transcriptomic Analysis Workflow.
Typical transcriptome analysis workflow consists of the steps shown in Figure 0.1.
First, a reference transcriptome and the expression data in the form of RNA-seq or mi-
croarray data are obtained (Barczak et al. 2012; Morens, Folkers, and Fauci 2004). The
reference transcriptome is a set of all transcript sequences, for each the samples can be
quantified against. Important thing to note is that not all organisms have the reference
transcriptome available, and when there is no publicly available reference, the investigator
must create one using de novo transcriptome assembly. In Chapter 1, I describe how I
constructed the de novo transcriptome reference of Rousettus aegyptiacus.
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With the reference and the sequence data, the quantification is performed to generate
the NxM expression matrix where each of N rows correspond to nth gene (or transcript
or probe, depending on the platform used) and columns correspond to mth samples. The
choice of quantification software depends on the data type(microarray, RNA-seq, or single
cell RNA-seq), the reference type (genome vs transcriptome) and the level of analysis(gene
vs transcript). The popular RNA-seq transcriptome quantification programs include, but
not limited to, tophat2 (Kim et al. 2013, STAR (Dobin et al. 2013), HISAT2 (Kim, Lang-
mead, and Salzberg 2015), RSEM (Li and Dewey 2011), and Kallisto (Pimentel et al.
2017). The individual cells contain the measurement for a particular gene in a particular
sample in the form of counts or expression measurements such as RPKM (Reads Per Kilo-
base of transcript per Million mapped reads) or TPM (Transcripts Per Million). With the
meta information, this expression matrix can then be analyzed via appropriate statistical
models. The majority of gene expression analysis tools for RNA-seq such as EdgeR, DE-
Seq2, limma-Voom, and Sleuth employs a generalized linear modeling framework (Degexp
et al. 2010; Law et al. 2014; Love, Huber, and Anders 2014; Pimentel et al. 2017; Robin-
son, McCarthy, and Smyth 2010a) with underlying likelihood model of negative binomial
with a factor with K levels in which k-th element corresponds to distinct biological states
such as normal, cancer, drugged, etc. Typically, the goal is to classify genes into positively
or negatively regulated groups in a particular biological state compared to a control group
and fold change is the parameter of interest. By observing the fold change, one performs a
differential gene expression analysis. The more advanced classification becomes necessary
with more meta information become available, which is a topic of Chapter 2 and Chapter 3
in this dissertation. Once the interesting subset of genes are identified, the knowledge base
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approach is used by the means of Gene Set Enrichment Analysis(Subramanian et al. 2005;
Yu and He 2016) or Pathway Analysis (Kra¨mer et al. 2013) to infer the biological pathways
or processes involved.
0.4 Organization of this Dissertation
A typical RNA-seq data analysis consists of multiple subcomponents as shown in Fig-
ure 0.1 and the granular components can be found more in detail in references such as
Conesa et al. 2016, but the two important components are 1) the reference transcriptome
and 2) the robust statistical methods to accurately estimate the various parameters of inter-
est while controlling the noise caused by technical and biological variances.
This dissertation revolves around these two themes as well as novel biological findings
I made with those two, and has a following progression:
In Chapter 1, I will discuss de novo transcriptome assembly of Rousettus aegyptiacus–a
species recently identified as a natural reservoir host of Marburg virus–which I comprehen-
sively built and characterized. Briefly, using deep RNA-seq data from 11 distinct tissues
from one male and one female, colleagues and I sequenced, assembled, and annotated the
reference transcriptome using the homology based approach. This transcriptome is a im-
portant resource for understanding bat immunology, physiology, disease pathogenesis, and
virus transmission.
In Chapter 2, I discuss the Multilevel Analysis of Gene Expression(MAGE) pipeline,
which I developed to fully utilize the structure of the data set and perform the direct infer-
ence based on the posterior distribution of all the relevant parameters. MAGE allows one
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to obtain samples from the posterior distribution of transformed parameters of one’s choice
whether it be log2Fold Change, tissue specificity, and waveforms, all of which allow one
to answer relevant and interesting biological questions.
In Chapter 3, I discuss the application of MAGE on the serially sacrificed rhesus
macaques infected with MARV virus. 15 rhesus macaques were sequentially sacrificed
via aerosol exposure to Marburg Virus Angola over the course of 9 days, and 3 types of
lymph nodes(tracheobrochial, mesenteric, and inguinal) were extracted from each sample
and sequenced for gene expression analysis. Multiple interesting biological insights have
been learned via posterior inferences supported by MAGE pipeline.
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Chapter 1
De novo transcriptome reconstruction and annotation of the
Egyptian rousette bat
1.1 Background
Bats (order: Chiroptera) constitute an abundant and diverse mammalian lineage compris-
ing approximately 20% of all known mammalian diversity (Wilson and Reeder 2005). Bats
have evolved apart from other mammals more than 50 million years (Moratelli and Cal-
isher 2015) and are divided into two major suborders; the Yinpterochiroptera (megachi-
roptera) and the Yangochiroptera (microchiroptera). Yinpterochiroptera includes the fam-
ily Pteropodidae and genera Rousettes and Pteropus whereas Yangochiroptera includes
the family Myotidae and genus Myotis (Teeling et al. 2002). Unlike most mammals, bats
can fly and this ability enabled their wide geographical range and increased metabolism
(Moratelli and Calisher 2015). Interestingly, bats have recently come to the forefront of
zoonotic disease research with vast number of pathogens identified in a wide-variety of bat
species (ibid.).
Upwards of 85 different viruses, primarily RNA viruses, have been detected and/or
isolated from bats (Calisher et al. 2006; Moratelli and Calisher 2015). Amongst these
are emerging viruses that cause lethal disease in humans and nonhuman primates in-
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cluding Nipah virus (Smith et al. 2011; Young et al. 1996), Hendra virus (Chua et al.
2000), severe acute respiratory syndrome (SARS)-like coronavirus (Li et al. 2005), Mid-
dle East respiratory syndrome coronavirus (MERS-CoV) (Groot et al. 2013), Marburg virus
(MARV) (Amman et al. 2015; Swanepoel et al. 2007; Towner et al. 2007, 2009), and Ebola
virus(EBOV) (Leroy et al. 2005; Ogawa et al. 2015; Sae´z et al. 2015). Despite the severe
virulence of these viruses in humans, infected bats are often asymptomatic (Amman et al.
2015; Middleton et al. 2007; Paweska et al. 2012, 2015; Swanepoel et al. 1996; Williamson
et al. 1998, 2000). Nipah virus and Hendra virus interactions with their natural reservoir
hosts, Pteropus vampyrus and Pteropus alecto, respectively, are well characterized. Exper-
imental infections of bats with high doses of henipaviruses have shown virus replication
and shedding with little to no disease (Middleton et al. 2007; Williamson et al. 1998, 2000).
Remarkably, the only viruses known to have induced any observable pathology in bats are
Rabies virus and Australian bat lyssavirus (Field, McCall, and Barrett 1999; Moratelli
and Calisher 2015). Understanding mechanisms of disease and differential responses to
infection in asymptomatic reservoir host species compared to species that exhibit severe
pathology will help inform the development of novel therapeutics and disease prevention
approaches.
Rousettus aegyptiacus, commonly known as the Egyptian rousette bat, has been iden-
tified as a natural reservoir host for MARV through ecological, epidemiological, and ex-
perimental studies (Amman et al. 2012, 2015; Paweska et al. 2012, 2015; Swanepoel et al.
2007; Towner et al. 2009). Furthermore, it has been speculated this bat could be a host of
Ebola virus (Feldmann and Geisbert 2011; Olival et al. 2013; Pourrut et al. 2009; Towner
et al. 2009), although recent experimental infection studies have shown Ebola virus does
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not replicate well in R. aegeyptiacus (Jones et al. 2015). The majority of human outbreaks
due to MARV have been associated with caves inhabited by R. aegyptiacus. Furthermore,
epidemiological surveillance of the R. aegyptiacus colony located in the Python cave in
Uganda revealed a biannual spike in Marburg virus prevalence. This pattern correlated
strongly with spillover transmission events in humans (Amman et al. 2012). Initial studies
in captive bats evaluated clinical signs, virus dissemination, and virus shedding patterns
during experimental infection with a MARV isolate derived from wild bats (Amman et
al. 2015). Consistent with a natural reservoir host, the bats showed little to no evidence
of disease even though the virus disseminated throughout their body and was actively shed
(ibid.). These results were confirmed when bats were infected with MARV Angola, a strain
isolated from a lethal human case (Paweska et al. 2015). In the absence of genetic and tran-
scriptomic information for R. aegyptiacus and with limited available reagents, studying this
reservoir host animal model has been challenging.
The rapid expansion in genomic knowledge for different bat species has facilitated
comparative studies that rely on the identification of genes and gene families, and has es-
tablished a framework for developing necessary reagents. Full genome annotations for
Pteropus vampyrus (2.63X, Ensembl), Myotis lucifugus (7X, Ensembl) Pteropus alecto
(110x, (Zhang et al. 2013)), Myotis davidii (110x, (ibid.)), and Myotis brandtii (77.8X,
(Seim et al. 2013)) are now available. Additionally, transcriptomic annotations for Ptero-
pus alecto (Papenfuss et al. 2012) and Artibeus jamaicensis (Shaw et al. 2012) have been
published. In particular, the complementary genome and transcriptome annotations for P.
alecto has aided studies on henipavirus infections in its reservoir host (Papenfuss et al.
2012; Zhang et al. 2013).
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Here, we report the transcriptomic annotation of R. aegyptiacus from a de novo assem-
bly of RNA sequencing data from 11 tissues isolated from a male and a female bat. We
identified 24,118 canonical coding transcripts whose expression profiles were consistent
with the corresponding tissues of origin. In addition, we identified and validated the novel
coding transcripts that do not have any homology with the known sequences. Furthermore,
we evaluated annotated immune-related genes and assessed the presence and expression of
genes associated with a variety of immune functions.
1.2 Results and discussion
De novo transcriptome assembly of R.aegyptiacus
We employed a de novo assembly approach to generate a comprehensive transcriptome
without relying on a genome reference. First, we generated 20 RNA-seq libraries consisting
of 11 tissue types (Table 1, Figure 1.1A) each collected from one male and one female R.
aegyptiacus bat, which yielded approximately 2.1 billion reads.
We then assembled the high quality reads using Trinity (Grabherr et al. 2011) (Figure
1.1B). This process generated 14,796,219 contigs. The assembly had high continuity and
coverage with a median number of 718,807 contigs and median N50 of 1,540 across all
tissues (Table 1). To comprehensively annotate the contigs, we used the Multiple Species
Annotation (MSA) pipeline (Lee et al. 2014), which leverages the homology of known
sequences of related species. We assigned gene symbols to contigs when this information
was available. This process clustered the contigs into isoform groups (Figure 1.1C).
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Figure 1.1: Schematic of the de novo transcriptome reconstruction and analysis
pipeline. The pipeline consists of 5 steps. A) Data generation: Multiple tissues are ex-
tracted from R. aegyptiacus and sequenced. B) De novo Transcriptome assembly: Individ-
ual samples are first preprocessed to remove adapter sequences and assembled into contigs
de novo. C) MSA annotation: Once the set of contigs is generated, they are annotated using
BLAST against three databases. In each step, unannotated contigs are iteratively annotated
using the downstream databases. D) Merging and Expression studies: A nonredundant
contig set is obtained by merging the contig set of individual tissues two at a time. This
pairwise merging is repeated until only one contig set is left. The subset of this contig can
be obtained for the downstream analysis such as gene expression analysis by taking the
transcripts with gene symbol and ORF sequence. See Figure 1.2 for details. E) Discov-
ery of Novel Coding Transcripts: Novel coding transcripts can be identified by searching
for contigs that failed annotation in the previous steps. Various metrics can be applied to
generate high confidence novel coding transcript candidates.
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Table 1.1: Sample Information and Basic Statistics.
Bat Gender Tissue Read count Library N50 Number of contigs
BAT01 F BM 67896687 single 1736 609943
BAT02 F BR 55004118 single 884 896445
BAT03 F HT 77315750 single 1263 717588
BAT04 F KY 59782352 single 1174 720026
BAT05 F LG 77510852 paired 1822 903831
BAT06 F LN 63170354 single 1566 638083
BAT07 F LV 89970603 paired 1566 697125
BAT08 F OV 75051316 single 1401 875888
BAT09 F PB 56553369 single 1890 404332
BAT10 F SP 56141808 single 1340 716771
BAT11 M BM 47988156 paired 1808 744115
BAT12 M BR 75378417 paired 1490 1088331
BAT13 M HT 20042200 paired 748 497729
BAT14 M KY 71478010 paired 1514 872829
BAT15 M LG 15525010 paired 668 575991
BAT16 M LN 88471565 paired 2186 797125
BAT17 M LV 27358079 paired 925 431513
BAT18 M PB 92707184 paired 1745 556053
BAT19 M SP 98465277 paired 2141 873259
BAT20 M TT 96476242 paired 1866 1179242
R.aegyptiacus transcriptome captures a majority of bat transcripts
We compared our assembly to the transcriptomes of three related bat species -- M. davidii,
P. alecto, and M. brandtii. Using BLAST, we recovered 90.1% of M. davidii transcripts,
89.54% of M. brandtii transcripts, and 97.38% of P.alecto transcripts. This result is consis-
tent with the evolutionary history of these bats considering that P. alecto and R. aegyptiacus
belong to the same family of Pteropodidae.
Combining the transcriptome to generate nonredundant contigs
Tissue-specific transcriptome assemblies contained different numbers of contigs, due to
their different levels of expression and sequencing depth. Without a common ground for
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comparison, it was difficult to perform downstream comparative analyses such as differ-
ential gene expression analysis; therefore, we combined contigs from all tissues into one
unified, nonredundant reference transcriptome (Figure 1.1D). To this end, we iteratively
merged the assemblies two at a time, similar to the approach employed in (Robertson et al.
2010) (Figure 1.1D). We obtained 4,746,293 nonredundant contigs. Among the nonredun-
dant contigs, 974,765 (20.54%) of the sequences were annotated by bat sequences, 860,578
(18.13%) by primate sequences, and 104,796 (2.2%) by sequences in nt database (Figure
1.2A).
Figure 1.2: Generation of Nonredundant Contig Set, Canonical Coding Transcript
Set, and High Confidence Novel Transcript Set. From the union of all contigs, we gen-
erated the nonredundant set of transcripts by iterative pairwise merging of contig set of all
tissues; this yielded 68% reduction of the contig set. A) To generate Canonical Coding
Transcript Set, we selected the contigs that are annotated with MSA pipeline. The anno-
tated contigs are further filtered for contigs that have a gene symbol. For an individual
gene cluster, we chose a transcript with the longest ORF to represent the corresponding
gene (Canonical Coding Transcript Set). B) For unannoated contigs, we selected for ex-
pression level, presence of an ORF with both start and stop codons in the CDS, and a min-
imum length of 400 nucleotides. We identified 8 high-confidence novel coding transcript
candidates for validation.
The nonredundant contig set had slightly lower sensitivity, though it still remained
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high; 86.60% of M. davidii, 85.95% of M. brandtii, and 95.30% of P. alecto transcripts
were recovered. The resulting annotated contigs were assigned gene names and combined
using the longest annotated ORF as the transcript. This results in an annotation for R.
aegyptiacus that contained a total of 24,118 genes. To determine the efficiency of using
the MSA pipeline, we determined that 84% (20,207 genes) of the contigs were annotated
using the bat database and 16% (3,911 genes) were subsequently annotated using the pri-
mate database. These data show that the MSA pipeline, which utilizes known transcripts
from related species only, is a sensitive and efficient method for de novo transcriptome
annotation.
Biological validity via expression analysis
We evaluated biological validity of the reconstructed transcriptome by analyzing global
expression patterns across the different tissues. If the transcriptome assembly and annota-
tions were accurate, the expression profiles of a given tissue should cluster with those of the
same tissue origin and segregate from those of different origins (Brawand et al. 2011; Lee
et al. 2014). A gene can result in more than one transcript isoform; therefore, to capture the
highest amount of information, for each gene, we focused on the transcript with the longest
open reading frame (ORF) (Figure 1.2A). After normalizing the expression values, we per-
formed Multidimensional Scaling (MDS) to determine the relationships between the gene
expression patterns in different tissues. As expected, MDS showed a clear separation of the
samples according to the tissue of origin (Figure 1.3A) and explains 74% of the variance
in the data.
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Figure 1.3: MDS of Gene Expression Profiles of Bat Tissues. A) We assessed the biolog-
ical validity and quality of our transcriptome annotations by performing Multidimensional
Scaling (using 1-spearman correlation as distance) on gene expression profiles of all tissues
using the 22,398 genes as feature vector. The first two coordinates explained 73.9% of the
variance in the data. B) We performed hierarchical clustering of expression profiles using
1-spearman correlation as distance. The clustering suggested presence of three groups that
correspond to separate developmental origins. Tissues used are Bone (BM), Brain (BR),
Heart (HT), Kidney (KY), Liver (LV), Lung (LG), Lymph (LN), Ovary (OV), PBMC (PB),
Spleen (SP), Testes (TT) of the male (M) and female (F) bat.
To examine the evolutionary relationship among tissues, we performed hierarchical
clustering of the gene expression profiles (Figure 1.3B). The brain, which has a different
developmental pathway compared to the other organs, was classified as an outgroup. The
spleen, lymph node, and bone marrow are all organs of the immune system and, as ex-
pected, clustered near each other. The peripheral blood contains some of the same cell
types as the immune organs, thus, clustered near these tissues. Lastly, the gonads and kid-
ney, which develop from the intermediate mesoderm, were grouped as neighbors in the
tree. These results suggest that our transcriptome captured sufficient heterogeneity of gene




We further assessed biological validity of our transcriptome assembly through gene ontol-
ogy (GO) analysis of tissue-specific expression profiles. We compared expression profile
of each tissue with the average expression in the whole dataset, and identified the top 200
most differentially expressed genes based on a generalized linear modeling framework.
Using this list, we examined the enriched GO biological process (BP) terms. Figure 1.4
shows the top 10 GO BP terms from the bone marrow, spleen, lymph nodes, and peripheral
blood mononuclear cells (PBMCs). (For other tissues, see Appendix 3.5). Terms enriched
for each tissue are consistent with their expected physiological functions.
Identification of immune-related transcripts
R. aegyptiacus is a natural reservoir host for MARV, allowing for virus replication and dis-
semination with little to no pathological consequences (Amman et al. 2015; Middleton et
al. 2007; Paweska et al. 2012, 2015; Swanepoel et al. 1996; Williamson et al. 1998, 2000).
One important aspect of reservoir host biology is how their immune response compares to
that of animal species that experiences severe disease, such as humans. Because of this,
we examined the transcriptome for the presence of immune-related genes. We associated
the R. aegyptiacus gene set with GO terms based on the human-specific gene ontology
annotation. This resulted in 14,781 genes that mapped to 14,817 GO terms. We used
CateGOrizer (Hu, Bao, and Reecy 2008) and applied the immune class GOSlim terms to
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Figure 1.4: Top Ten Enriched Gene Ontology Biological Process Terms for bone mar-
row, spleen, lymph node, and PBMC. In each panel, the terms are listed in descending
order of significance of enrichment. These tissues, in particular are associated with differ-
ent aspects of the immune system and these associations are observed within the GO BP
terms identified.
identify immune-related genes from this set. Similar to previous studies in P. alecto and
A. jamaicensis, we found that out of 14,817 GO terms, approximately 2.75% were associ-
ated with immune response (Papenfuss et al. 2012; Shaw et al. 2012). Amongst the most
represented GO terms were cytokine production, lymphocyte activation, T cell activation,
regulation of apoptosis, and regulation of lymphocyte activation (Figure 1.5).
We next searched for specific genes related to various aspects of the immune response
in other mammals, primarily mice and humans. We started by evaluating the annotation
of the transcriptome for the presence of anti-viral genes. A multitude of pattern recogni-
tion receptors were identified including toll-like receptors (TLRs) 1-9, RIG-I, MDA5, and
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Figure 1.5: Distribution of immune genes within the R. aegyptiacus transcriptome at
the GO Slim level using CateGOrizer. Genes annotated in the transcriptome were as-
sessed for association with the immune response by analyzing them with CateGOrizer
using the immune class GO Slim terms. The frequency shown is the percent of immune
class GO slim terms associated with that particular pathway out of all the GO terms that
were identified.
LGP2 along with the important scaffold and signaling molecules Myd88 and MAVS. A va-
riety of antiviral molecules were also found, including Mx1 and Mx2, PKR, STING, IRF3,
IRF5, IRF7, members of the IFIT and IFITM families, and ISG15. We also looked for
the presence of type I, II, and III interferons (IFN). We were able to identify IFNgamma,
IFNgamma2, and IFNal pha. Transcripts corresponding to the IFN receptor subunits IF-
NAR1 and IFNAR2 were also identified. IFNal pha and IFNbeta have been previously
characterized by cloning from stimulated cells (Omatsu et al. 2008). To eliminate the pos-
sibility that IFNB was not identified because of an impaired assembly, we aligned reads
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prior to assembly to the IFNB sequence from P. alecto (NCBI Eukaryotic genomes anno-
tations) (Figure 1.6).
Figure 1.6: Alignment of R. aegyptiacus reads to P. alecto transcripts. The pre-
processed reads are aligned to the interferon and immunoglobulin transcripts of P.
alecto obtained from NCBI Eukaryotic genomes annotations and Papenfuss et al. 2012.
The two sequences(IFNA4 Palecto and IFNB1 Palecto) used are XM 006918336.1 and
XM 006918337.1, respectively.
Only 2 reads from R. aegyptiacus were detected which provided insufficient coverage
to construct the transcript. These data suggest that IFNB expression in healthy tissues of
R. aegyptiacus is low. This is consistent with other mammals in which IFNB is primarily
expressed after exposure to a stimulus.
We then searched the transcriptome for genes associated with innate immune cells. We
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found the genes CD14 and CD11c, which are useful for phenotyping macrophages and
dendritic cells, as well as CD80 and CD86, which are useful for evaluating the activation
status of these cells. Genes associated with natural killer (NK) cells, however, were much
less obvious. We were able to identify the co-receptor CD56, but not CD16. Genes en-
coding for molecules in the killer cell lectin-like receptor (KLR) family, including NKG2A
and NKG2D, were also not found. In other bat transcriptomes, coverage of NK cell-related
genes was sparser than that of other mammals (Papenfuss et al. 2012; Shaw et al. 2012).
These data suggest that expression of NK cell-related genes are either not present or present
at low levels in R. aegyptiacus or that bats may contain a different NK cell receptor reper-
toire than other species.
Next, we examined the repertoire of genes associated with adaptive the immune re-
sponse. We identified a variety of genes associated with T cell identification, activation,
inhibition, and differentiation including CD3ε , CD4, CD8a, CD25, CD69, CCR7, PD-1,
CTLA4, GATA3, foxp3, and Tbet. Interestingly, we were able to identify genes for the
TCRα and TCRβ chains, but were unable to find transcripts for the TCRδ and TCRγ
chains. The transcriptome annotation for P. alecto included these genes, but they were at
low levels (Papenfuss et al. 2012). This supports the notion that αβ T cells are the predom-
inant T cell subset in bats. We also looked at genes associated with B cells and were able
to find CD19, CD20, CD27, as well as transcripts that were similar to the immunoglobulin
heavy chains A, E, G, and M and the immunoglobulin light chains κ and λ . Future analy-
sis of the R. aegyptiacus genome would be useful in evaluating the immunoglobulin gene
repertoire.
Finally, we studied the cytokine and chemokine repertoire, important for shaping both
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innate and adaptive immune responses. We found a variety of transcripts corresponding to
a wide array of both pro-inflammatory and anti-inflammatory cytokines. These included
IL-2, IL-4, IL-5, IL-6, IL-12a, IL-12b, IL-17a, IL-23, IL-10, TGFβ , TNF, IFNγ , IL-1β ,
CCL2, CCL5, and CXCL10. Altogether, the reference transcriptome generated for R. ae-
gyptiacus provides an excellent foundation for investigating reservoir host immunology in
bats.
Novel Transcripts
There were 2,806,154 unannotated contigs from the nonredundant contig set (Figure 1.2B).
Of those, 71.6% (2,008,503 contigs) did not have an ORF suggesting the majority of these
contigs may be noncoding transcripts. To determine if the unannotated contigs were real
or artifacts from the assembly, we used BLAST to align this set of contigs to the P. alecto
genome and found that 96% (2,706,432 contigs) were aligned. To evaluate the possibil-
ity of an incomplete or impaired assembly, we grouped the aligned contigs into a total of
1,012,664 clusters based on the presence of overlapping sequences. This reduction sug-
gests that multiple isoform expression patterns between different tissues may have affected
our assembly or that our short read assembly may have been incomplete. Nonetheless, the
number of unannotated contigs that aligned to the P. alecto genome suggests that many of
these contigs, either coding or noncoding, may be novel transcripts shared within the order
Pteropodinae. Future studies evaluating the conservation and possible functions of these
sequences will be useful to determine the importance of these genetic elements. To vali-
date novel contigs in R. aegyptiacus that appeared to be coding we utilized PCR. Primers
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were designed to produce amplicons for eight highly expressed, unannotated contigs that
contained ORFs longer than 400 bp. Using RNA isolated from the spleen, we were able to
produce amplicons of the expected size from at least one bat (Figure 1.7 and Appendix 1).
Figure 1.7: Unannotated, novel transcripts from R. aegyptiacus were validated of by
RT-PCR. RNA from the spleen of both bats was reverse transcribed to make cDNA.
The cDNA was amplified using primers specific for one of 8 novel transcripts that were
unannotated in the assembly, but contained a complete ORF larger than 400 nucleotides.
The expected product sizes were: transcript 1, 457bp; transcript 2, 450bp; transcript 3,
419bp; transcript 4, 548bp; transcript 5, 469bp, transcript 6, 277bp; transcript 7, 507 bp;
and transcript 8, 301bp.
The sequences of these amplicons were found to match the expected sequence from
the assembled ORF of the unannotated contig. These contigs also showed high sequence
similarity to the P. alecto genome. In particular, six of the 8 validated transcripts showed
sequence similarity higher than 75% at a query coverage greater than 64. The other two
validated transcripts had a query coverage of 23 with 78.36% identity (transcript 1 in Fig-
ure 1.7) and a query coverage of 7 with 91.27% identity (transcript 2 in Figure 1.7) (Ap-
pendix 3.5); therefore, we hypothesize that these transcripts might be specific to R. aegyp-
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tiacus. Further investigation is needed to fully understand the characteristics and biological
functions associated with the proteins these contigs encode.
1.3 Conclusion
In this section, we presented the comprehensively annotated of transcriptome of
R.aegyptiacus and assessed its quality and biological validity. This transcriptome will be
an important resource to study bat immunology. In particular, it will facilitate the process
of investigating differences in host responses between asymptomatic reservoir host species
and species that exhibit severe pathology. It will also pave the way for the development of
novel therapeutics and prevention approaches against emerging zoonotic virus outbreaks.
1.4 Material and Methods
Sample preparation
Tissues and blood were collected from one male and one female adult R. aegyptiacus
bats that were bred and housed at the colony established at the Center for Disease Con-
trol and Prevention, Atlanta, GA, USA (Amman et al 2015). Approximately 100mg
of the following tissues were collected and homogenized in 1mL of Trizol LS (Invit-
rogen, Carlsbad, CA): liver(bat id:BAT7, BAT17), lung(BAT05, BAT15), heart(BAT03,
BAT13), kidney (BAT04, BAT14), brain(BAT02, BAT12), axillary lymph nodes (bilateral,
pooled) (BAT06, BAT16), spleen(BAT10, BAT19), bone marrow(BAT01, BAT11), and go-
nad(BAT08, BAT20). PBMCs(BAT08, BAT18) were isolated from the blood and stored in
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Trizol LS as well.
RNA was extracted using the PureLink RNA Mini kit (Invitrogen, Carlsbad, CA).
cDNA was synthesized using the TruSeq Stranded Total RNA Sample Prep Kit (Illumina,
San Deigo, CA) according to the manufacturer’s protocol. The libraries were evaluated
for quality using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). After quan-
tification by real-time PCR with the KAPA qPCR Kit (Kapa Biosystems, Woburn, MA),
libraries were diluted to 10nM. Cluster amplification was performed on the Illumina cBot
and libraries were sequenced on the Illumina HiSeq 2500. Eight of the female bat libraries
were single-end, while the remaining tissues from the female bat and all tissues from the
male bat were paired-end. All of the libraries sequenced were 125 bp in length. The aver-
age library depth was 66M reads (minimum 16M and maximum 98M).
Ethics Statement
All experimental procedures were conducted with approval from the Centers for Disease
Control and Prevention (CDC, Atlanta, GA, USA) Institutional Animal Care and Use Com-
mittee, and in strict accordance with the Guide for the Care and Use of Laboratory Animals
(Committee for the Update of the Guide for the Care and Use of Laboratory Animals 2011).
The CDC is an Association for Assessment and Accreditation of Laboratory Animal Care
International fully accredited research facility. No human patient-derived clinical materials
were used in these studies.
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De novo transcriptome assembly
We first examined the quality of the reads using FastQC v0.11.3 (FastQC). We also
preprocessed the reads to remove the adapter sequence using cutadapt v1.5 (Martin
2011). We removed “AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC” from the
forward strand and “AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCG-
GTGGTCGCCGTATCATT” from the reverse strand. We performed strand-specific de
novo transcriptome assembly using Trinity r20140413p1 (Grabherr et al. 2011) with the
parameters: “–normalize reads” and “–SS lib type FR”, along with its default parameters
for all of our samples.
Homology based annotation of the transcriptome
For annotation of contigs and clustering them into a gene model, we used Multiple Species
Annotation pipeline, an nucleotide-based annotation approach that is more efficient and
faster than BLASTX (Lee et al. 2014). To make a BLAST (Altschul et al. 1997) database
for bats, we started with the complete “Nucleotide collection” (nt) database. We exported
all accession numbers of the bat sequences at NCBI and made a subset database from
nt using “blastdb aliastool -db nt -dbtype nucl -gilist bats.sequence.gi.txt -title Bats -out
Bats”. Using the same type of query, we also created a database for primates including
humans due to their extraordinarily well-annotated transcriptomes, which will maximize
the power of our annotation pipeline. We then used BLAST to iteratively align the contigs
to the bat db, the primate db, and finally nt using a subtractive approach: what did not align
to the bat db was aligned to the primate db, and what did not align to the primate db was
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aligned to nt.
Sensitivity of R.aegyptiacus transcriptome
To assess the coverage of our transcriptome, we downloaded the M. davidii, P. alecto, and
M. brandtii transcriptomes from NCBI Eukaryotic genomes annotations (NCBI Eukaryotic
genomes annotations). We generated a BLAST index out of union of all contigs from
our samples, and aligned the three bat contigs to our BLAST databases. We chose the
alignment with 70% of sequence identity with maximum evalue of 1e-4.
Nonredundant transcriptome assembly
To generate a nonredundant set of contigs, we iteratively merged individual assemblies
using the the methods similar to the (Robertson et al. 2010) employed to merge the kmers.
Using CD-HIT-EST v4.6 (Li and Godzik 2006) with sequence identity threshold of 0.99,
we merged the first two pairs of contig sets (of sample i and sample i+ 1) upto the final
sample n. After each iteration, we merged the resulting merged contig sets using a similar
approach until only one contig set remained.
Canonical Coding Transcript Set
For the expression profiling, we generated a reference transcriptome consisting of tran-
scripts each representing a gene model according to the following method: We first used
TransDecoder(r20140413p1) (TransDecoder) to find the ORF of all transcripts. Then,
based on the MSA pipeline, we chose a transcript with gene symbols and the longest ORF
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in each gene cluster to capture the most information for downstream expression analysis.
We did not consider the contigs mapped to nt database in this manuscript because obtain-
ing feature files for all sequences in as a requirement of MSA pipeline was computationally
impractical and a majority of the gene symbols (24,118) are captured in the bat and primate
databases.
Gene expression and Gene Ontology analysis
After a canonical transcript set was obtained, we used this as a transcriptome reference
for expression analysis. We mapped the preprocessed reads to this reference using RSEM
v1.2.19 (Li and Dewey 2011) and obtained a gene-to-count matrix. We removed the tran-
scripts with expression variance equal to zero or with low expression (count <= 10). For
MDS plot, we used the spearman correlaton as a distance measure and “cmdscale” from the
“stats” package in R (R Core Team 2015). To explore the biological processes in each gene
expression profile, we employed a one-to-all sample comparison using the EdgeR gener-
alized linear model framework (McCarthy et al. 2012; Robinson, McCarthy, and Smyth
2010b) . For each tissue, we compared individual gene expression within the tissue versus
the average expression of all other tissues. With each tissue having differently ranked gene
lists, we then selected top 200 genes and ran gene ontology analysis using topGO (Alexa
and Rahnenfuhrer 2010) with human-specific gene ontology annotation (Ashburner et al.
2000).
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Analysis of unannotated transcripts and Identification of novel
transcripts and validation
We used BLAST (Altschul et al. 1997) to align unannotated contigs to the genome of P.
alecto with the evalue of 1e-4 and query coverage of 40%. To cluster the aligned contigs
into groups, we used bedtools (Quinlan and Hall 2010) setting the distance threshold pa-
rameter at 0. For transcripts that did not align with any similarity to bat, primate, or nt
BLAST databases, we applied a series of filters to select for the coding transcripts to be
validated. We used the following criteria: an ORF that was complete with both a start and
stop codon, an ORF that was at least 400bp in size, and a transcript that was expressed
(a read count > 0). We further selected for the novel transcripts with usuable primers us-
ing primer-BLAST (Ye et al. 2012). Using these criteria, the number of novel transcripts
was narrowed down to a total of 8. The primers and expected amplicon size are listed in
Appendix 1.
For validation, RNA was extracted from the spleen tissue of both the male and female
bats using Trizol LS (Invitrogen, Carlsbad, CA). cDNA was synthesized from 2.5 µg of
RNA using the Superscript III First-strand Synthesis SuperMix (Invitrogen, Carlsbad, CA).
Amplicons for each of the primer sets were generated using Phusion HotStart Flex DNA
polymerase (New England BioLabs, Ipswitch, MA) and run on a 1.5% agarose gel for vi-
sualization. The correct size amplicon was gel extracted, quantified, and Sanger sequenced
on the Applied Biosystems 3730x1 DNA Analyzer.
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Chapter 2
Multilevel Analysis of Gene Expression
Although the price of the high-throughput genomic and transcriptomic experiments have
dropped significantly over the years, the number of libraries used in RNA-seq samples
remain relatively small because of its exploratory nature, budgetary constraints, and ethical
issues involving animal samples. Typical the number of biological replicates obtained
for individual groups in RNA-seq experiments is three (Conesa et al. 2016), and many
techniques have been developed to address this so-called “small n high p problem” such
as edgeR or DESeq. However, as the experiment becomes more complex with increasing
number of factors, which are interacting among themselves, it calls for a more sophisticated
technique.
In this chapter, I will describe the motivation of statistical framework titled Multilevel
Analysis of Gene Expression (MAGE) which collaborators and I developed to address the
aforementioned challenges, in particular, the RNA-seq study involving the serially sac-
rificed rhesuses infected with Marburgvirus specified in Chapter 3. We also provide the
theoretical justification and validation via posterior predictive checks for MAGE.
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2.1 Background
Traditional approach to tackling Gene Expression Analysis
Despite the ease of ability to quantify the global gene expression with the help of microar-
ray or RNA-seq, it comes with another set of challenges. The data generated from high-
throughput sequencing technology is stochastic and therefore robust statistical method is
needed to estimate the underlying parameters of interest.
Normalization is one issue when different experimental units have different exposures,
and one must adjust them for the fair comparison. However, the more important issue is
the small number of replicates within each group. Even though it was possible to measure
thousands of genes, only a handful number of samples, usually three (Conesa et al. 2016),
could be used for an experiment because of a fixed budget and ethical issues. This results
in lack of power and susceptibility to erroneous signals.
The numerous statistical tools that have been developed to analyze the high-throughput
gene expression data both for microarray and RNA-seq (Auer and Doerge 2010). For mi-
croarray, the unit of measurement is the intensity whereas for RNA-seq gene expression
are measured in the form of read counts. In a microarray, the gene expression value ranges
reside in real numbers, but with RNA-seq, the read counts are in the non-negative inte-
gers. The majority of gene expression analysis tools for RNA-seq such as EdgeR, DESeq2,
limma-Voom, and Sleuth uses employs a generalized linear modeling framework (Degexp
et al. 2010; Law et al. 2014; Love, Huber, and Anders 2014; Pimentel et al. 2017; Robin-
son, McCarthy, and Smyth 2010a) with underlying likelihood model of Poisson or Negative
Binomial with a factor with K levels in which k-ith element corresponds to distinct biologi-
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cal states such as normal, cancer, drugged, etc. In general, the parameters of interest are the
means of K groups for a particular gene. To compare the means, the log2(mu2mu1 ) is computed
and its significance is used to determine if it’s worth further exploration for the downstream
analysis such as GSEA (Subramanian et al. 2005).
The challenge associated with these algorithms is to estimate the parameters of the
model with the small number of experimental units. The core algorithm for DESeq (Deg-
exp et al. 2010) or EdgeR (Robinson, McCarthy, and Smyth 2010a) is designed to accu-
rately estimate the dispersion parameter in a negative binomial assuming that genes with
the similar expression levels have more or less similar dispersion parameter. Voom (Law
et al. 2014) and Sleuth (Pimentel et al. 2017) first log transform the count data so that the
reads are in the shape of the normal distribution and then regularize variance via shrinkage
approach roughly similar to DESeq.
All these tools are usually built for the case when the factor of interest is one. As the
cost of RNA-seq drops, investigators started to perform experiments with more complex
designs. When one has a multiple covariates such as time and tissue, the traditional linear
model with the small sample size falls short. Another weakness of these classic tools is that
they provide the estimated parameters in the form of point estimates. If one tries to explore
the transformed parameters, the uncertainty might not be adequately accounted for.
Another variable of concern in the gene expression analysis is time. Since the biological
process is a dynamic system, there is an immense interest in understanding the relationship
between time and gene expression. For example, one may be interested in how a set of
genes that change upon infection of a particular virus. When there is a dimension of time
in one’s gene expression data, however, the model becomes more complex to capture the
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variance embedded in the temporal information (Bar-Joseph, Gitter, and Simon 2012; Spies
and Ciaudo 2015). The classic tools mentioned in the previous section are optimized for
the static gene expression analysis. There have been approaches to tackle time course
RNA-seq data using approaches such as splines (Storey et al. 2005), Bayesian approach
(Aryee et al. 2009), Gaussian Processes (Bar-Joseph et al. 2003; Heinonen et al. 2014), or
mixed effect model (Sun et al. 2016). However, the majority of these tools have not been
specifically developed for the RNA-seq data. Most of the time course data were done using
microarray technologies (Aryee et al. 2009; Storey et al. 2005) or qPCR (Heinonen et al.
2014) and only for the case involving two groups (Sun et al. 2016). Therefore, the need
for the flexible tool for analyzing the RNA-seq experiment with the complex experimental
design is warranted.
2.2 Multilevel Analysis of Gene Expression
To address the challenges of analyzing an RNA-seq experiment with a complex experimen-
tal design involving many parameters, we developed the novel high-throughput gene ex-
pression analysis pipeline titled Multilevel Analysis of Gene Expression(MAGE). MAGE
attempts to tackle gene expression analysis problem using a fully Bayesian approach and
multilevel(hierarchical) modeling technique. This approach is useful in incorporating prior
information, analyzing the quantity of interest to address complex statistical questions, and
capturing the uncertainty inherent in the noisy system. With MAGE, one can take the set
of raw RNA-seq read inputs and transform them into the full Bayesian posterior samples
of the parameters of interest, with which one can perform useful statistical inference on
34
biological questions at hand. It combined the best practices of gene expression analysis,
Bayesian statistics, and multilevel(hierarchical) modeling. Thanks to the advent of prob-
abilistic programming languages such as Stan (Carpenter et al. 2016), it is also easy to
improve and extend the underlying model. This has an additional beneficial effect in that
researchers do not have to learn new and different tools to try multiple different models.
Instead, they can use the metrics such as Leave-one-out cross-validation (LOO) and the
widely applicable information criterion (WAIC) to compare and evaluate separate models
to choose the best model (Vehtari, Gelman, and Gabry 2017). In Figure 2.1, the schema of
MAGE pipeline is shown.
Motivation of each component of MAGE
Gene Expression Analysis
MAGE follows the typical framework of RNA-seq data analysis (Degexp et al. 2010;
Robinson, McCarthy, and Smyth 2010a in that it models the count data with the gen-
eralized linear models (GLM) (Nelder and Baker 1972), in particular, negative binomial
distributions. The benefit of this approach–as opposed to log transformation of counts,
the approach taken by Law et al. 2014; Pimentel et al. 2017–is it has excellent theoreti-
cal framework for modeling count data (Nelder and Baker 1972) while accounting for the
biological variability via overdispersion parameter. Furthermore, GLM provides you with
the interpretability of estimated coefficients. For example, in the one factor model with
two levels, the coefficient of a level corresponds to the log fold change with respect to the
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Figure 2.1: MAGE Pipeline Schema. A) Gene expression quantification B) Probabilistic
Model Fitting C) Inference. An arrow represents dependency relationship. A parallelo-
gram icon represent the output file from the previous step. a grey-colored round rectangle
represents a particular process, implemented in a script. A document icon represents a
reference file obtained either externally or from another file
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reference group1. This ease of interpretability is important for classification purposes for
the downstream analysis such as GSEA or pathway analysis.
Bayesian Statistics
The Bayesian statistical framework comes with many benefits such as incorporating prior
knowledge, regularizing parameters, having interpretability and extensibility (Gelman and
Hill 2007; Gelman et al. 2014). In frequentist approach, parameters are considered as fixed
constant values; in contrast, in Bayesian, parameters are viewed as random variables that
have probabilistic nature. By adding prior information for parameters, one can incorporate
known information that might not be present in the data or have parameters share informa-
tion among one another in a robust manner. In Bayesian statistics, the first class object is
the posterior probability of parameters given the data. With a posterior distribution, rather
than a point estimate, one can transform the parameters however one wants to address the
questions at hand statistically and compute expected values to answer interesting ques-
tions. Furthermore, incorporation of prior information becomes almost necessary when
one tries to estimate a lot of parameters as a result of complex structure with not enough
data to prevent under- or over-fitting (Gelman and Rubin 1995). Our goal is the accurate
estimation of parameters of interest with the small number of replicates–a typical scenario
in the high throughput gene expression data analysis–and without prior information, the
estimates become unreliable.
1If µx = exp(bx) and µy = exp(bx+bx−y), then bx−y = log(µy/µx).
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Multilevel modeling
When there is multiple group information associated with data, as is the case with the data
with complex experimental design, the number of parameters to estimate increase. This is
because the system is usually modeled with the set of indicator variables whose cardinal-
ity increases as the number of levels increase. With more than one factor, estimation of
parameters become unstable without imposing additional structure (Gelman et al. 2014).
MAGE attempts to address this issue by employing multilevel modeling–also known as
hierarchical modeling– where information from covariates are shared to stabilize the in-
ference (Gelman and Hill 2007; Gelman et al. 2014). With multilevel modeling, there
are usually fewer parameters are necessary to fit and the particular characteristics of the
groups are learned from the data (McElreath 2015). Additional benefits of multilevel mod-
eling include, but not limited to, its ability handle imbalance data, which is prevalent in
the real world, stable and accurate estimation of parameters, and accounting for the vari-
ations between and within groups (ibid.). In addition, multilevel modeling can be viewed
in the framework of the bias and variance trade-off. Ignoring the group structure leads to
highly bias estimate whereas estimating parameters for individual group naı¨vely can lead
to high variance. The former is called “complete pooling” approach whereas the latter “no-
pooling”(Gelman et al. 2014). Multilevel modeling targets for something in between in a
theoretically sound manner.
We attempt to bring this idea to the development of MAGE, combining Bayesian statis-
tics and multilevel modeling to the high-throughput gene expression analysis. The ad-
vantage of MAGE is that it is general, flexible to effectively analyze the high-throughput
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sequencing experiments with the added interpretability delivered by the accurate estimation
of relevant parameters.
Data description
As shown in Figure 2.1, the input data of the first step of the MAGE pipeline is the fastq
files of N libraries (Figure 2.1A). Each library n can be first quantified by using RNA-seq
gene expression quantification program such as Kallisto. The result of this operation is
the vector of length G where each element corresponds to the expression level of the gene
g for the library n in the form of count. N number of vectors can be combined into a
G×N expression matrix. There is a separate table that contains the meta information for
individual s libraries such as library size, tissue, or time labels. The expression matrix and
the meta table are the input for the MAGE model described in the following section.
Model specification
MAGE has a following generative model specification 2 (Figure 2.2). In a typical high
throughput gene expression analysis, we have G genes, each of which are represented as a
vector of length N which is the number of libraries. We fit G separate models for individual
genes g. The generative model is that for each of the sample n in each gene g, we draw
yg[n] reads from Negative Binomial(NB) distribution with the mean µg[n] and the inverse
dispersion parameter φg.
2The initial version of MAGE was built for the study described in the Chapter 3, but the model can be
modified easily for different studies with different experimental designs.
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Figure 2.2: Graphical Model of probablistic model used in MAGE. Standard plate nota-
tion is employed. A empty node represents a random variable and a colored node represents
the observed variable or meta information. An arrow between nodes represents a condi-
tional relationship in which the target node is conditinally dependent on a source node. A
plate represents a group of variables with its cardinality shown in the bottom right corner.
There are N libraries, G genes, D Day Post Infection (DPI) groups, T tissues, and D x T
interaction terms. L represents a (effective) library size for nth library. For a particular
library n and gene g , there are y a read, φ a dispersion parameter, b0 a intercept, and other
betas the group specific parameters.
yg[n] ∼ NB(µg[n],φg)
We choose NB to model because 1) yg[n] is realized as count data, 2) can account for
overdispersion induced by the biological variability, and 3) a popular choice of probability
distribution to model RNA-seq count data in many packages (Love, Huber, and Anders
2014; Nueda, Tarazona, and Conesa 2014; Robinson, McCarthy, and Smyth 2010a). The
dispersion parameter can be either a plug-in estimate(via a package such as edgeR) or es-
timated from the data as a parameter in the MAGE model. The particular parameterization
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which has the following mean and variance specifications.




We assume that the mean µg[n] has a following structure that the support of the mean
within the non-negative range:
µg[n] = Ls[n]exp(θg[n])
Where Ls[n] is the depth of the library s for a nth sample and θg a linear sum of pre-
dictors. In other words, we use the expontential function as a link function with a offset
term log(Ls[n]), which is equivalent to a model-based normalization approach employed
in edgeR (Robinson, McCarthy, and Smyth 2010a). One can use the raw library size or
TMM-normalized effective library size (Oshlack, Robinson, and Young 2010). We set
θg[n] as follows.
θg[n] = β0+βzdpi[n] +βztissue[n] +βzdpi x tissue[n]
Here, we denote dpi[n] as one of D Day Post Infection (DPI) labels, tissue[n] as one
of T tissue labels, and dpi x tissue[n] as one of DxT DPI and tissue labels for nth sample.
The model assumes that there is a baseline effect β0(intercept) and the rest of the terms are
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the deflections based on the membership of a sample to a particular group, which can be
obtained from the meta table. In the model, there are two main effects--dpi and tissue-- and
the interaction between the two factors. The interaction term is necessary because there
is the substantive reason to believe that the different tissues will have different expression
profiles across days. For individual coefficients other than intercepts, we put the hierar-
chical structure on the prior which has the effect of learning them adapatively from the
data (McElreath 2015), which is one of the novel contributions to the existing approaches





Here we use a weakly informative prior for the intercept; For standard deviation3, we
chose the value 10, which is a relatively large number in a log scale. We did this to accom-
modate the dynamic ranges of various gene expressions and different library sizes. With
the library of a million reads 106 ∗ exp(−10) corresponds to 45 read counts. Regardless
of the interpretation, the choice of a particular number in the weakly informative prior has
the little influence on estimation of parameters (hence the adverb “weakly”) (Gelman et
3In Stan, the normal distribution is parameterized with mean and standard deviation, as opposed to mean
and variance
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al. 2014; Kruschke 2013). For the non-intercept terms, we put the multilevel structure to
learn the parameters from the data. For hyper-parameters, we used the following weakly
informative priors for regularizing effects (Gelman et al. 2014).
µdpi,µtissue,µdpixtissue ∼ N(0,5)
σdpi,σtissue,σdpixtissue ∼ hal fCauchy(0,2)
We chose 5 for standard deviation to stay conservative in effects of the factors. We
chose the half-cauchy distribution to model all the scale parameters, which can be viewed
as a t-distribution with one degree of freedom, for its flexibility of handling not only the
near origin but other parameter spaces to capture outliers and is a recommended choice for
default prior for variances (Gelman 2006; Polson and Scott 2012).
Computation
To implement and fit the model to the data, we used Stan, a probabilistic programing lan-
guage which compiles a given model to C++ and uses an Hamiltonian Monte Carlo (HMC)
engine to draw posterior samples from the given model (Carpenter et al. 2016). In Stan,
we used nonstandard parameterization to speed up the sampling process. The stan code is
attached in the Appendix 3.5). We find that 1000 from 4 chains are sufficient to achieve
MCMC convergence for our datasets; however this could be different for different datasets.
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2.3 MCMC Convergence Diagnostics
Since we obtain the posterior distributions from the iterative simulations of Hamiltonian
Monte Carlo sampling via Stan, we must assess whether MCMC sampling converged to a
target joint distribution. The standard way of doing this is the visual diagnostics via trace
plots. The central idea is to run multiple chains of MCMC and see if they mix well, which
is a sign of the well covered posterior distribution of a given parameter. If the mixing does
not occur, it is a sign of pathological cases. However, to do it for thousands of genes is
not scalable and intractable; Alternative heuristics that can be used to diagnose MCMC
convergence is to compute and monitor the potential scale reduction statistics called Rhat
(Gelman and Rubin 1992)–the ratio of within chain variance to between-chain variance
–for each parameter using samples from multiple chains. If the convergence has occurred,
this statistics should be close to 1. The rule of thumb is that each of the model parameter
should reach Rhat below 1.02 (Brooks and Gelman 1998).
The most important set of parameters of interest is the fold change. In Figure 2.3, we
see that the majority of Rhat values computed are below the recommended value of 1.02.
2.4 Posterior Predictive Checks
The gold standard way of validating your model is to test the model against the unseen
future data. This way we know that our model has learned the general data generating
process. Usually, this is done via form of train-test data separation, leave one out cross
validation, or k-fold cross validation (Friedman, Hastie, and Tibshirani 2001). However,
this is not feasible in our case we only have a few data points and it is very costly to generate
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Figure 2.3: MCMC convergence diagnostics. Rhats for 167,016 fold changes(12 fold
changes for each of 13918 genes) are below the recommended convergence threshold of
1.02, which suggests the MCMC convergence.
the data. Another approach to testing your model is to do simulation and assess type 1 and
2 error, which is a common way to validate your model. However, in our case, it’s not that
simple because we do not know the underlying data-generative process.
Posterior Predictive Checks is a way to validate one’s model (Gelman et al. 2014).
The idea is to compare the simulated samples from a proposed model to observed data to
see if the posterior distribution well approximates a target distribution. If the simulated
samples are drastically different from the data, it suggests that the current model needs an
improvement.
In Figure 2.4, we plot the qqplot between predictive distribution and the empirical count
for DDX58, NPC1, and group of genes. Predictive distributions of read counts are obtained
by simulating the read count from the parameters being estimated (See “generated quan-
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Figure 2.4: Positive Predictive Checks for DDX58, NPC1, and Group of Select Genes.
In each panel, qqplot is plotted between empirical counts and predictive counts sampled
from posterior distribution. The top, middle, and bottom panel shows the qqplot for
DDX58, NPC1, and group of selected genes. Select genes are the genes in which 50%
are samples have expression greater than 0 read count
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tities” in Stan code 3.5). We observe that the simulated data generated from our model
are more or less similar to the actual data for genes that have low expression (NPC1),
high expression (DDX58), and average genes, which have more than 50% non-zero read
count). The prediction of MAGE overlaps well with the actual data, which suggest that
the model has accurately captured the structure well and be trusted for the inference in the
downstream analysis.
2.5 Benchmark
To assess the validity and performance of the Bayesian approach taken by MAGE pipeline,
the synthetic expression data with two experimental conditions was generated consisting
of genes with known parameters selected from following:
• Mean expression level E ranging between 10 and 1000 with the step size of 5
• Dispersion D ranging between 0.5 and 2 with the step size of 0.1
• Expression state S of a gene: ”no change”, ”up regulated”(2 fold change), ”down
regulated”(0.5 fold change) with respect to individual gene’s corresponding baseline
mean expression value.
Furthermore, different experimental settings were generated based on the combination
of following parameters:
• Proportion of differentially expressed genes P: 1%, 10%, or 50%
• Number of biological replicates per condition N: 3, 10, and 50
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The code to simulate the data is in Appendix 3.5. The idea is to test the performance
of MAGE in three different settings: easy, middle, difficult where N=50, 10, and 3, respec-
tively using one factor model in both MAGE and EdgeR, a classic and popular gene ex-
pression analysis package to compare the performances (Robinson, McCarthy, and Smyth
2010a). EdgeR is shown to have a high sensitivity and a specificity compared to other gene
expression analysis packages (Rapaport et al. 2013).
With EdgeR, the default GLM workflow was used, and for MAGE, the same hyper-
parameters and likelihoods as the previous section were used. The code used in the bench-
mark is in Appendix 3.5.
The important parameter of interest in applications that motivated the development
of MAGE is a fold change (FC) between conditions because it can be used to perform
differential gene expression analysis and dimensionality reduction (See the Section 2.6 and
also Chapter 3). Therefore, the mean absolute error (MAE) with respect to the known FC





where G is the total number of genes. In EdgeR, the MLE estimate of FC was used
and for MAGE, posterior median FC was used. MAE is computed for various expressions
settings defined above. We computed each MAE using the three different simulations to
add confidence intervals.
Output of the benchmark is shown in Figure 2.5. While both methods struggled when
the number of biological replicates(N) was low, MAGE had lower MAE in all different
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Figure 2.5: Benchmark of MAGE Performance Using Synthetic Data Compared With
EdgeR.
possible configurations of N. The fact that MAGE consistently outperformed EdgeR in
each setting in this simple benchmark of one factor model provides a confidence on the
accuracy and robustness of the Bayesian approach employed by MAGE.
2.6 Applications
With the full posterior distributions, transforming the parameter and obtaining the Monte









Where q is a parameter of interest in the model, t is a function, S is the number of
MCMC draws. That is, the expected value of any transformed parameter is a function of
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the posterior distribution, and can be easily and accurately estimated with MCMC samples
(Betancourt and Girolami 2015; Carpenter et al. 2016).
Armed with this knowledge, one can do all the classic tasks such as computing the fold
change. For example, log2 fold change between dpi3 and dpi1 in Tracheobronchial Lymph
Node (TbLN) can be computed with following:



















where D represents the data, s the sth sample in the posterior. To compute the log2FC
in a tissue between two dpis, first the group specific parameters(such as dpi1/tbln and
dpi3/tbln) are computed by combining the corresponding main effects and interactions.
Then, their difference is computed which denotes the log fold change and the coefficients
are computed in the log scale. The change of base is applied to make it in the log2FC
scale. The visualization of the log2FC for three issues and various dpis with respect to
corresponding dpi1 is shown in Figure 2.6.
One can compute the high density interval (HDI) to capture the region that covers α %
of the distribution (Kruschke 2014):
HDIα(θ) = (L,U),L,U ∈ R and L <Us.t.
argmin(U−L)Pr(L≤ θ ≤U) = α
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Figure 2.6: Marginal Posterior log2 Fold Change for DDX58 .
Red line indicates the mean within each group
HDI has a better interpretability than the frequentist confidence interval in that the
former denotes a most likely region for a given parameter whereas the latter has a slightly
different meaning; α% confidence interval represents the percentage of the theoretical con-
fidence intervals that would contain a true parameter. In Chapter 2, we used HDI to perform
the differential gene expression analysis.
2.7 Bayesian Differential Gene Expression Analysis
With the full joint posterior distribution, one can perform differential gene expression
analysis in the framework of Bayesian decision theory. In general, there are two ways
to make a decision in a Bayesian framework: Bayes Factor(BF)-based and Parameter
Estimation(PE)-based methods (Kruschke and Liddell 2017). BF-based method constructs
two separate models–null and alternative–where the former has a degenerate prior on a
point mass(i.e. 0) and the latter has a diffuse prior over parameter values. With these
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The goal is to choose the model explains the data best between the two competing models
using this metric. Commonly, if BFnull is greater than a threshold such as 10, the null
model is accepted; On the contrary, if BFnull is less than 110 , the alternative model is chosen
instead. However, the usefulness of BF-method is shown to be limited (Gelman et al.
2014; Kruschke and Liddell 2017). For example, when the null prior probability is low
or the models that are continuous rather than discrete, BF-based method might lead to the
bias.
Another approach of making a decision is PE-method guided by HDI and the Region
Of Practical Equivalence (ROPE) around the null value, the interval of values considered to
be virtually null to account for the inherent uncertainty of the parameter values (Kruschke
and Liddell 2017; Kruschke 2014). The procedure is following: if α%−HDI is completely
outside of ROPE, the null value is rejected and if α%−HDI is completely inside the ROPE,
the null value is accepted. The benefit of the PE-based approach is that it’s intuitive, simple
to perform, and general. Kruschke 2014 et al. extensively reviews the superiority of ROPE
over BF in Kruschke and Liddell 2017; Kruschke 2014. To apply the PE-method to identify
differentially expressed genes (DEG), we can obtain the posterior distribution of log2FC
as mentioned in the previous section, choose the size of HDI, the ROPE-radius and the
null value, and check if the given gene meets the criteria to be considered as differentially
expressed. For example, we can construct the following algorithm to determine if a gene is
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DEG:
1. lower bound of HDIα(log2FC) is greater than γ , OR
2. upper bound of HDIα(log2FC) is less than -γ
where α corresponds to the size of HDI(i.e., 90%) and γ corresponds to the radius of
the ROPE around 0. The Chapter 3 shows an application of this DEG algorithm.
2.8 Limitations
Currently, the limitations of the MAGE pipeline is that fitting all genes is computationally
intensive. Although fitting individual genes with 4000 MCMC draws using Stan takes less
than 30 seconds, the challenge is that it must be done so for about 20,000 genes. We
addressed that challenge by fitting models in parallel using the Sun Grid Engine, which
might not be available to general users. The current solution for a general user is using the
clusters from Amazon Web Service(AWS) or a computer with multiple cores.
The parallelization sheds light on another limitation of MAGE: genes are assumed to
be independent of each other. By making this assumption, we might have missed the ad-
ditional parameter information that could have learned from combining all genes into one
model. However, the benefit of making independence assumption for genes outweighs the
cost. Performing MCMC algorithm to estimate parameters from a fully joint model that in-
cludes all genes will make the computation prohibitively slow. An open avenue of research




In this chapter, we developed Multilevel Analysis of Gene Expression to accurately es-
timate the parameters of the gene expression model involving time course RNA-seq data
using multilevel modeling and Bayesian approach. We showed the motivation and theoreti-
cal justification for MAGE and the validness of the proposed model via posterior predictive
checks and feasibility of fitting thousands of simultaneous models by providing the vari-
ous MCMC diagnostics. To our knowledge, MAGE is the first framework that applied the
full Bayesian approach to gene expression data analysis. With the powerful and flexible
multilevel modeling, the posterior draws for each gene in a particular biological system are
provided, and with them, one can conduct a powerful and biologically interesting inference.
The majority of the tools currently available are optimized for a simple one factor model,
and more powerful tool is needed when the the number of factors increase while the exper-
iment units stay the same. We were able to implement MAGE thanks to the development
of probabilistic programming language such as Stan that provides a general framework of
modeling and parallel computational resources that are becoming increasingly common-
place. The model is easy to extend and modify depending on the data set at hand. The
software is available at https://github.com/RabadanLab/mage
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Chapter 3
Transcriptomic evaluation of the host response to aerosolized
Marburg virus Angola exposure in the lymph nodes of Rhesus
macaques
3.1 Background
Marburg virus (MARV) is a single strand, negative-sense RNA virus that belongs to the
order Mononegavirales, the family Filoviridae, the genus Marburgvirus. Its functions are
performed by the seven proteins encoded in its 19 kb long-genome--nucleoprotein (NP),
VP35, VP40, glycoprotein (GP), VP30, VP24, and the polymerase (L).
Despite its simple composition, MARV is considered as one of the deadliest pathogens
along with its close relative Ebola virus (EBOV) for its high infectivity and virulence
(Brauburger et al. 2012; Mohamadzadeh, Chen, and Schmaljohn 2007; Slenczka and Klenk
2007). Classified as a biosafety level-4 (BSL-4) pathogen, MARV is capable of causing
severe hemorrhagic fever disease in humans and Non-Human Primates (NHP) with symp-
toms including but not limited to fever, rash, malaise, diarrhea, vomiting, excessive bleed-
ing, severe liver damage, and coagulation complication (Brauburger et al. 2012). With no
clinically approved antivirals available currently, MARV poses a significant threat of pan-
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demic and bioterrorism (Brauburger et al. 2012; Feldmann and Kiley 1999; Kiley et al.
1982; Kuhn et al. 2010; Nakayama and Saijo 2013).
MARV is first discovered and isolated in 1967 in the former Yugoslavia and the city of
Marburg in Germany--hence its name--when laboratory workers became sick while han-
dling the African Green Monkeys (Chlorocebus aethiops) imported from Uganda (Siegert
1972). Since then, it has caused a number of sporadic outbreaks (Gear et al. 1975; Johnson
et al. 1996; Nikiforov et al. 1993; Smith et al. 1982) between 1970s and 1990s, followed
by two major outbreaks. The first major MARV outbreak occurred in Durba, Democratic
Republic of Congo (DRC) in 1998-2000 (Bausch et al. 2006), and the second major out-
break was in Uige Province in northern Angola, West Africa in 2004-2005 (Towner et al.
2006). In each case, the case fatality rate reached 83% (128 reported number of death) and
90% (227 reported number of death), respectively (Brauburger et al. 2012; Chronology of
Marburg Hemorrhagic Fever Outbreaks 2014) (Figure 3.1). The former outbreak was a
case where multiple strains of marburgvirus were introduced whereas the latter outbreak
was caused by a single strain. These outbreaks collectively demonstrated highly infectious,
pathogenic, and easily transmissible nature of MARV.
How is MARV so virulent in human and non-human primates? In the past, MARV
and EBOV have been shown to trigger potent dysregulation of both innate and adaptive
immune responses in both nonhuman primates and humans (Bosio et al. 2003; Brauburger
et al. 2012; Mohamadzadeh, Chen, and Schmaljohn 2007). Initially, MARV targets sentinel
cells such as dendritic, monocytes, macrophages in lymph nodes, liver, and spleen. In the
late stage, MARV is rapidly replicated and disseminated to other organs (Brauburger et al.
2012).
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Figure 3.1: History of Marburg Virus Outbreak. MARV was introduced in 1972. There
have been sporadic outbreaks between the 70s and 90s. There were two major outbreaks
of MARV in late 90s and early 2000. A blue bar represents the number of exposed cases
and the red bars the number of fatal cases.
However, the exact mechanism of MARV pathogenesis in animal hosts remains elusive.
For example, Rousettus aegyptiacus, the recently identified host of MARV (Towner et al.
2007, 2009), is asymptomatic to virus; in contrast, to human and NHP such as Rhesus
macaques, the pathology is severe.
There are features of MARV that render its research difficult. MARV is fatal to human
and NHP if left untreated, and the time to death after the infection can range from 1 to 2
weeks (Geisbert et al. 2007; Mohamadzadeh, Chen, and Schmaljohn 2007). Furthermore,
mouse models are not useful in MARV research as they do not fully recapitulate MARV
disease phenotype of human. Rhesus macaques is an NHP model for MARV infection
(Nakayama and Saijo 2013), but they are expensive to maintain and process, especially
with the ban of import of Indian origin research. Nonetheless, the transcriptomic charac-
terization of the natural host and spillover hosts such as NHPs or humans would contribute
to our understanding of factors involved in the pathogenesis and host-virus interaction.
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The present study explores the transcriptomic response in lymph nodes of Rhesus
macaques to aerosolized Marburg virus Angola exposure. We chose lymph nodes for their
importance in the immune response to infection and virus dissemination.
Cell lines and primary cells in a peripheral blood mononuclear cell (PBMC) have been
used to investigate gene expression of hosts infected with MARV (Connor et al. 2015; Lin
et al. 2015). However, the transcriptomic view of Marburg virus infection on the tissue
samples of animal hosts will better characterize the host response to MARV at the site of
infection and the secondary tissues. This will open the door for better understanding of
immunology and expedite the development of effective treatments.
To characterize the immune responses to MARV in lymph nodes of rhesus macaques
on a molecular level, 15 rhesus macaques were sequentially sacrificed via aerosol exposure
to Marburg Virus Angola. Over the course of 9 days, and 3 types of lymph nodes (Tra-
cheobronchial, Mesenteric, and Inguinal) were extracted from each sample and sequenced
for the gene expression analysis.
With the novel pipeline MAGE discussed in Chapter 2, we obtained the posterior dis-
tribution of parameters relevant to expressions of 13,918 genes, with which we performed
several biological inferences including differential gene expression analysis, pathway anal-
ysis, unsupervised expression archetype identification, and tissue-specific differential gene
identification.
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3.2 Results and Discussion
Data, Study Design, and Analysis Strategy
In Figure 3.2, the analysis pipeline is shown along with the data description and study
design. Briefly, to characterize the global gene expression pattern and individual gene ex-
pression changes, 15 rhesus macaques have been simultaneously infected with MARV via
aerosol route. They were grouped into a group of three and each group has been sacrificed
serially over 9-day post-infection (DPI) to Marburg virus, with 2 days apart from each
group. Three lymph node tissues (Tracheobronchial (TbLN), Mesenteric (MesLN), and
Inguinal (IngLN)) have been extracted from each rhesus macaque, and RNA-seq data were
generated.
With the RNA-seq data, the quality for individual libraries were checked first. Total of 6
samples was dropped due to a low number of reads (See 3.5). Figure 3.3 shows the pattern
of sample quality. After selecting the suitable transcriptome reference (see the next section
(3.2)), the quantification of transcriptome was performed. The gene counts for each sample
have been piped into the MAGE pipeline (Chapter 2) to estimate the posterior distribution
of relevant parameters including dispersion, log2 Fold Change (log2FC), and baseline ex-
pression. Once the joint posterior distribution was obtained in the form of MCMC samples,
the various biological analysis were performed and discussed in the Section 3.3.
Reference Selection
One of the most important decisions for the RNA-seq analysis is a choice of a reference
sequence against which reads are to be mapped (Conesa et al. 2016) since it determines
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Figure 3.2: Data, Study Design, and Analysis Strategy. A) Tissue extraction: three
lymph nodes--tracheobrochial, mesenteric, and inguinal-- have been extracted from an in-
dividual monkey; B) Study Design: 5 groups of three rhesus macaques have been serially
sacrificed post exposure to MARV infection via aerosol route. Each group have been sacri-
ficed at day post infection (DPI)1, 3, 5, 7, and 9 and tissues were extracted, processed, and
sequenced; C) Analysis Pipeline: Analysis comprise three major steps 1) gene expression
data generation 2) probabilistic modeling via MAGE, and 3) statistical inference using the
posterior draws. Multiple sub-steps comprise each of the major step.
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Figure 3.3: Number of reads for individual library RNA-seq libraries. The number of
reads are plotted for individual libraries in dpi and tissue groups. Color represents unique
rhesus samples. Starred are the libraries that are excluded due to low number of reads.
the feature space on which the analysis is performed. Multiple reference genome and tran-
scriptome resources are available for rhesus macaques (Aken et al. 2016; Gibbs et al. 2007;
O’Leary et al. 2015; Peng et al. 2014; Zimin et al. 2014). For the present study, our desider-
ata were to use the reference transcriptome with the high sensitivity (that the majority of
sample reads are captured in the reference sequences) and high specificity (that there are
less extraneous sequences in the reference transcriptome) as well as good annotations. To
this end, we compared the three reference resources: 1) Refseq transcriptome based on
RheMac2 genome (O’Leary et al. 2015), 2) Ensembl transcriptome based on RheMac2
(Aken et al. 2016), and 3) MacaM transcriptome (Zimin et al. 2014). After checking the
percentages of reads mapped and percentage of reference sequences with no reads mapped
(Figure 3.4), we confirmed that MacaM has both high sensitivity and specificity. We used
MacaM for the downstream analysis discussed in the next section.
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Figure 3.4: Choosing the reference transcriptome for quantification. Each dot repre-
sents a unique RNA-seq library. Different colors represent quantification using different
annotation resources. Lines were fitted using linear model. Ideally, a good annotation has
both high percentage of reads mapped, and low percentage of reference sequences with no
reads mapped.
3.3 Statistical Inference
Posterior Viral Load Estimated via RNA-seq
To characterize the viral transcriptome in the rhesuses infected with MARV, we quantified
the viral reads and obtained posterior log2FC and baseline expression (See Method 3.5).
Since we did not have the day 0 (control) samples, to compute the fold change, we used
day 1 as a reference sample. This is justified by the fact that viral load is non-existence
(Figure 3.5B). Considering the day 1 post infection as a reference, Posterior Log2 Fold
Change was computed for subsequent DPI time points(day 3, 5, 7, and 9). In Figure 3.5A,
we observe the high correlation between the viral load and posterior median log2FC with
respect to dpi1 within a tissue. Over the days, however, the viral load increases dramatically
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by the order of magnitude, with TbLN spikes up the quickest with 20 median log2FC at
DPI3 (Figure 3.5C). This showed that the hosts were unable to antagonize the rapid viral
replication of MARV.
Figure 3.5: Posterior Viral load Estimated via RNA-seq and MAGE. A) Correlation
Between posterior median viral Fold Change and Viral Load posterior median log2
Fold change can be used to predict the viral load measured independently ; B) Base Ex-
pression of MARV Base expression of MARV is near 0; C) Posterior Log2 Fold Change
of MARV As the DPI increases, the viral load spikes up in all three tissues
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Global Expression Pattern of MARV infection in rhesus
The quantification of viral genes illustrated that the viral growth rapidly has increased.
We were then interested in determining the host response to this MARV growth. To this
end, we processed 13,918 individual host genes using the MAGE pipeline (Chapter 2).
To view the gene expression pattern of MARV infection in rhesus macaques globally, we
obtained the posterior median log2FC for individual genes and performed the principal
component analysis on the gene to fold change matrix (Figure 3.6). We used log2FC rather
than TPM or count as features due to the baseline expression differences among tissues
(See Appendix 3.5). The first two dimensions of eigenspace collectively explained 53.1%
variances in the expression profile represented by posterior log2FC. We first noted that the
U-shaped topology of the projection of samples on the eigenspace is consistent with the
ordering of day post infection. Interestingly, the PC1 axis seems to represent the genes
involved in the early and late infection signatures whereas the PC2 axis represents the
transcriptional signatures that are active the mid-infection stage. We also noted that the
samples were clustered by DPI indicating that the activity of the distinct transcriptome
profile in the time course of MARV infection.
Differential Gene Expression Analysis
Next, we were interested in the biological processes occurring in each DPI in each tis-
sue. To identify the set of differentially expressed genes (DEG) over time in each DPI,
we compared each DPI group to DPI1 in each tissue to obtain the log2FC. Since we have
the posterior distribution of log2FC, we defined that gene expression for a gene is differ-
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Figure 3.6: Principal Component Analysis using Median Log2 Fold Change. Points
represent the individual dpi groups; shapes represent tissues.
ential if the two parameters--absolute log2FC and high density interval (HDI)-- satisfy the
following conditions:
1. upper bound of HDI90(log2FC) has to be greater than 1.5, OR
2. lower bound of HDI90(log2FC) has to be less than -1.5
We chose these thresholds to capture the genes with strong effect sizes (the read count
approximately 2.8 times higher/lower than that in dpi 1) and statistical confidence (90%
of the probability mass is above/below the threshold). We tested the grid of parameters
(Figure 3.7) and the relative amount of DEGs was more or less consistent among different
parameter sets.
Overall, the DPI increase results in the number of genes.
Interestingly, there are more up-regulated genes than down-regulated genes in MARV
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Figure 3.7: Tuning the parameters for Differentially Expressed Gene Analysis. The
bar above the horizontal line corresponds to the number of up-regulated genes where as the
bar below corresponds to the number of down-regulated genes.
Figure 3.8: Differentially Expressed Gene at HDI 90% and abs(log2FC) > 1.5.
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infected samples. This maybe due to the fact that immune systems are actively engaged
upon infection which requires the production of signaling molecules such as cytokines and
chemokines and immune effector genes such as interferon stimulated genes. In fact, many
genes that are differentially expressed are immune related. Furthermore, the number of
DEGs is the highest in TbLN followed by MesLN, and IngLN (Figure 3.8). This is also
consistent with the fact that TbLN serves as the draining lymph node and primary site
of immune response activation. Indeed, the number of differentially expressed genes are
correlated with the viral load (Pearson correlation of 0.73, p-value =0.008).
Pathway Analysis
We now were interested in combining individual gene expression information and inferring
biological pathways that might be enriched. To perform pathway analysis, we uploaded
gene expression tables for each lymph node at each time after infection into the Ingenuity
Pathway Analysis (IPA) program. The data was filtered using the same parameters as we
used previously to identify differentially expressed genes (abs(log2FC) > 1.5 , HDI0.9).
We then ran core analyses on all 12 data sets using DEG genes. This yielded information
for each lymph node at each time point. We focused on the canonical pathways enriched
in each tissue with a p-value ¡ 0.05 and found that 27 pathways are enriched in all 3 lymph
nodes during the course of infection (Figure 3.9) and that 27 pathways are enriched only in
the TbLN during infection (Figure 3.10).
The top 5 pathways that are enriched amongst all lymph nodes evaluated relate to an-
tiviral host responses and immune cell activation and migration. Similar to the patterns
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Figure 3.9: Canonical Pathways Shared among Tissues. p-value indicates the overlap
p-value between the gene set and our data set computed using Fisher’s Exact Test
observed in the number of DEGs in each tissue, the immune pathways are enriched first in
the TbLN followed by the MesLN and IngLN which corresponds to the kinetics of MARV
replication which occurs first in the TbLN followed by the other LNs. With TbLN being the
draining lymph node, we expect to see an increase in immune cell migration and activation
in this tissue shortly after infection.
Later during infection, we observe enrichment of pathways that correspond to the acute
phase response, macrophage function, and the complement system. We also see enrich-
ment of coagulation-related pathways which agrees with previous data that MARV infec-
tion results in late stage coagulopathies as well as the appearance of fibrin deposits and
thrombi in tissue sections of the TbLN. Furthermore, we also see enrichment for a vari-
ety of metabolic pathways which may be a result of virus infection and the disruption of
normal cellular function and/or a results of tissue damage induced during MARV infection.
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Figure 3.10: Canonical Pathways in TbLN only.
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The pathways that are enriched only in the TbLN are again primarily associated with
the immune response. Rather than being only antiviral and macrophage-specific responses,
we now see enrichment of pathways that deal with regulating and coordinating innate and
adaptive response including those pathways that focus more on development and skewing
of T and B cell responses. Again, this further supports the TbLN as the draining and prim-
ing lymph node for mounting and coordinating the immune response to aerosolized MARV
infection. These pathways are most highly enriched 5 days after infection, after which point
the enrichment scores(-log(p-value)) decline. This correlates with what is observed during
histological analysis of the TbLN where tissue architecture, in particular germinal center
formation is maintained through 5 days after infection, but becomes abolished by 7 and 9
days after infection correlating with an increase in lymphocytolysis and apoptosis as deter-
mined by TUNEL staining (data not shown). Interestingly, lymph node tissue architecture
is mostly maintained in the MesLN and IngLN through 9 days after infection with little to
no apoptotic cells. Previous studies on MARV pathogenesis have shown that a decrease
in lymphocytes and dysregulated immune response occur later during infection and con-
tribute to disease pathogenesis (Geisbert et al. 2008, 2009). These data suggest that part of
this immune destruction is occurring in the draining lymph node.
Unsupervised Clustering to Uncover Expression Archetype
In the previous section, we analyzed the gene expression profiles by mapping the DEGs
to the knowledge base provided by IPA. This is useful for the identification of activity or
inhibition of the known pathways at a particular time point. In addition to known pathways,
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we were also interested in characterizing the archetypical expression patterns existing in
the expression profile as a whole.
Bar-Joseph et al. illustrated archetypical trends common in genes in biological systems
in Bar-Joseph, Gitter, and Simon 2012. The patterns they described include “Sustained”
pattern in which an expression level of a gene continually increases or decreases as a func-
tion of time or“Impulse” pattern in which there is a spike of an expression followed by the
rapid decrease.
Since we have a full posterior distribution of the system, we can transform it to identify
the trends that exist in our expression profile. To this end, we transformed the posterior
log2FC into the rank distribution with 1 being the lowest fold change and 5 being the
highest fold change. In effect, we generated the posterior distribution for the 120-category
nominal variable which level corresponds to the possible rank of a log2FC, which we refer
as “waveform”. With this, we can identify, for example, the set of genes with the upward
trend(“1,2,3,4,5”) and those with the downward trend(“5,4,3,2,1”).
We looked at the most frequent waveform patterns in all genes (Figure 3.11). Inter-
estingly, we observed that the distribution of waveforms is not uniform; there are certain
waveforms that are more frequent than the others. For example, the top patterns com-
prise the waveforms that have ranked the dpi7 and dpi9 as rank 4 and rank 5, respectively,
indicating that majority of genes are up-regulated in the later days.
Next, since each gene has 120 possible waveforms in each of three tissues, we com-
puted the entropy for those probabilities for individual genes and compared the distribution
of entropies among tissues (Figure 3.12).
Given that the upper bound of the entropy for the given probability vector is approxi-
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Figure 3.11: Top 30 Most Frequent Waveforms in 13918 Genes. y axis represents the
the sequential rank of log2FC and x-axis represents frequency
Figure 3.12: Waveform Entropy for 13918 Genes in Different Tissues.
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mately 6.91(Log2(120), the majority of the genes are near 6, which suggests that the major-
ity of genes do not have a skewed pattern. However, we see that the distribution of TbLN
is lightly skewed left followed by MesLN indicating that genes in TbLN and MesLN have
more pronounced patterns than those in IngLN on a global scale. This is consistent with
the fact the physical locations of these tissues and the route of infection.
To uncover the number and the type of archetypical expression using both direction and
magnitude of expression in an unsupervised fashion, we used the Mapper algorithm which
is based on topological data analysis (TDA) techniques (Carlsson 2009; Singh, Me´moli,
and Carlsson 2007). Recently, The effectiveness of TDA has been demonstrated in many
applications in biology for its ability to reduce the dimensionality while preserving the
topological features of original multidimensional space (Ca´mara 2017; Rizvi et al. 2017;
Singh, Me´moli, and Carlsson 2007). Mapper, in particular, is an algorithm that takes the
point cloud in the high dimensional space and attempts to represent it in the low dimension
by reducing them into simplicial complexes. Representing individual genes as a vector
of posterior median Log2 fold changes at DPI 3, 5, 7, 9, and considering only the genes
that have at least one differential log2FC (as specified in the Section 3.3) in any DPIs,
we obtain a 788x12 matrix, which can be viewed as a point cloud with 788 points in the
12-dimensional space. After applying the z-score transformation on each dimension to
prevent the late days log2FC biasing the inference, we performed the mapper algorithm
using Ayasdi (Carlsson 2009; Lum et al. 2013 . The output of the Mapper is a network
in which a node corresponds to a set of observations (in our case, genes) and the edge
corresponds to the existence of a shared element between nodes. Elements in each node
are determined by the nearness of observations in the original higher dimensional space.
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We chose the resolution of 30 and gain of 3 in the parameters for Mapper for the
downstream analysis (See Method 3.5) to create the network shown in Figure 3.13. In
this network, there are 6 clusters detected via the community detection algorithm (See
Method 3.5). The next panel shows the archetypical gene expression within each clus-
ter for each tissue. Interestingly, cluster 1 captures the continually down-regulated genes,
whereas cluster 4 captures gradually increasing genes. Cluster 2 and cluster 5 consists
of genes that spike up after DPI 5, but the former has the higher magnitude. These sets
of genes might be interesting to further explore since these are the ones that have higher
expression in the late stage of infection. Cluster 3 seems to contain genes that go up in
day 3 and down in dpi5 but goes back up in dpi7 and dpi9 whereas cluster 6 seem to have
different patterns among tissues.
Figure 3.13: Gene Clusters.
We further examined the genes exclusively present in each cluster, as shown in Ta-
ble 3.1, and performed the gene ontology enrichment analysis to capture potential biologi-
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Table 3.1: Genes in Clusters Induced By Mapper. Red colored genes are the genes
reported to be differentially expressed in peripheral blood mononuclear cells of rhesus
infected with MARV by Connor et al.(Connor et al. 2015)
cal processes that might explain the data.
In Table 3.2, the top 5 gene ontology terms are shown for each cluster.
The cluster 1 contains the continually down-regulated genes, and the notable genes
are CD40LG, LTA, and CXCR2 (fig:cluster1˙genes). For example, CD40LG and LTA
encode for proteins which are the members of TNF superfamily and primarily produced in
lymphocytes of many types. The rapid decrease in their expressions may be associated with
lymphocyte apoptosis, lymphocyte migration, or independent down-regulation mechanism
during infection. Further studies are required to pinpoint the exact cause.
Interestingly, the majority of GO terms corresponding to the cluster 4 corresponds to
immune pathways. Indeed, we capture the important immune genes such as IL6, IFNG,
IL1B, and CCL2. The GO terms with strong significance show up in cluster 2 and 6, which
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Table 3.2: Top 5 Enriched Gene Ontology Terms in Each Clusters.
Figure 3.14: Genes in cluster 1.
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are related to metabolic pathways and developmental pathways. It is important to keep in
mind that the genes that are annotated with a particular GO term might have drastically
expression pattern(i.e., genes that are anti-correlated), and thus this analysis may not fully
uncover the biological meaning behind our archetypical gene sets. Further studies are
necessary to study individual clusters or a set of genes in each cluster to identify potentially
novel biological markers, receptors, and immune effector genes.
Identification of Tissue-specific Genes
We wanted to identify the set of genes that have a unique pattern in a particular tissue
compared to other tissues. This is in part motivated by the fact that phenotypically TbLN is
drastically different the other two lymph nodes. To that end, we first defined the Day-wise
Tissue Specificity Score (DTSS) for each gene g at a particular dpi d. In particular, DTSS
is defined as the posterior probability with the following criteria:
1. Effect Size Difference: |log2FCg,d(t)− log2FCg,d(x)|> κ
2. Uniqueness: −ζ < log2FCg,d(x)< ζ
Where t is a target tissue and x is the tissue that is being compared. In other words,
log2FC of tissue t at dpi d has to be greater than log2FC of tissue x at dpi d by κ to ensure
high effect size difference, and log2FC of tissue x (the one that is compared against) should
have a small magnitude ζ to ensure uniqueness for d and no changes for x.
For illustration, we look at the DTSS at dpi 9 for TbLN against IngLN computed with
posterior samples for DDX58 and TMEM97 in Figure 3.15. We chose these genes to
illustrate the two cases, the one which would yield the low DTSS and the other the high
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DTSS. We set κ and ζ to be 1. With DDX58, we can see that at dpi9, it is not preferentially
expressed in TbLN compared to IngLN because it has low effect size difference and low
uniqueness, resulting in low DTSS (3.75%). In contrast, with TMEM97, the effect size
difference is high and the expression is unique in TbLN, resulting in high DTSS (92.83%).
Figure 3.15: Day-wise Tissue Specific Score for DPI9 and TbLN.
Since we have the joint posterior distribution, we can compute the three sets of joint
tissue specific score (JTSS) scores for global (G-JTSS), early (E-JTSS), and late (L-JTSS)














|log2FCg,d(t)− log2FCg,d(x)|> κ ∧|log2FCg,d(x)|< ζ

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In other words, JTSSs are derived from DTSS contributing to individual days and in-
dividual tissues that are being compared. In Figure 3.16), we show the top 10 G-JTSS,
E-JTSS, and L-JTSS for TbLN, MesLN, and IngLN.
Figure 3.16: Joint Tissue Specific Score.
We noted that there are no genes that have preferential tissue expression throughout in-
fection, indicated by the low posterior probability. When we look at E-JTSS and L-JTSS,
we see that TbLN has several genes that have a relatively high posterior probability for
tissue specificity. For example, CASP4, IRF1, and DYNLT1 are positively regulated in
the early stage of infection in TbLN only. Interestingly, in MesLN,the majority of the top
genes are down-regulated in the early stage of infection, but the posterior probabilities are
low compared to others. In the last stage of infection, there are two genes that have the
high posterior probability of L-JTSS, NUB1 and TMEM97. In particular, TbLN specific
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late gene TMEM97 is interesting in that it is known to be a negative regulator of NPC1
(Ebrahimi-Fakhari et al. 2016), which is a protein required for filovirus entry (White and
Schornberg 2012). Why would MARV let a protein down-regulate the proteins required
for entry? There are a couple of potential explanations for this observation. One hypoth-
esis that MARV actively down-regulate its own host protein for some unknown purposes.
It has been reported that some virus is known to negatively regulate its host receptor; for
instance, Hepatitis C Virus is known to down-regulates the host receptor CD81 required for
entry (Ke and Chen 2013); the reason for phenomenon still remains unclear. Another hy-
pothesis is the up-regulation of TMEM97 may be counterbalanced by post-transcriptional
or translational modifications for degradation. Further studies are necessary to investigate
this seemingly paradoxical event.
Interactive MARV Infection Gene Expression Viewer
To facilitate the spread of information and generating hypotheses, we developed the inter-
active web application using R Shiny (Chang et al. 2017). With this tool, a user can view
the genes in 40 different immune pathways (Figure 3.17) and how their log2FC change
over time.
This is useful for obtaining a holistic view of pathway members gene expression profile
changes upon MARV infection.
If users are interested in knowing the baseline expression and the log2FC for individual
genes, they can do it at “Baseline & Posterior log2FC” in the web application 3.18.
This is a great tool to generate hypothesis and validate the output from pathway
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Figure 3.17: Interactive Gene Expression Viewer - Immune pathway. An end user
can explore the gene expressions of the set of genes associated with a particular immune
pathways.
Figure 3.18: Interactive Gene Expression Viwer - Gene Explorer. A base expression
and log2FC for a particular gene can be queried
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analysis. For example, the pathway analysis from Figure 3.9 indicated “Interferon Sig-
naling” related genes are enriched. We can see from Figure 3.18 the pathway mem-
ber OASL is indeed up-regulated over DPI. What is nice about seeing log2FC over
time is that we can view the kinetics are different among tissues; there is a delay of
OASL transcription between TbLN and IngLN. The expression viewer can be accessed
at https://rabadan.c2b2.columbia.edu/marburg.
3.4 Conclusion
In this chapter, we explored the global characterization of transcriptional profile changes of
three lymph nodes of rhesus monkeys upon infection of MARV. We demonstrated the mul-
tiple biological findings powered with the posterior samples provided with MAGE pipeline
discussed in Chapter 2. First, we showed that the viral load can be accurately predicted
with MAGE posterior and showed that the amount of viral RNA goes up over time, indi-
cating active viral replication in the samples. The MARV replication is shown to be the
fastest in TbLN, potentially because it is a draining lymph node. We then looked at the
global expression pattern via PCA; infection patterns are distinguished in each dpi group,
and infection pattern nicely divides into early and late stages. For differential gene expres-
sion analysis, DEG goes up as DPI goes up, but it’s the highest in TbLN. Pathway analysis
reveals that innate systems are activated in all three lymph nodes, but with slight of de-
lay in MesLN and IngLN compared to TbLN. Among the differentially expressed genes,
there are six gene expression archetype groups, which we identified via Mapper algorithm.
Lastly, we identified a set of early and late genes that are preferentially expressed in TbLN.
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The biological findings and the visualization tool provided in this study will contribute to
the better understanding of host responses to MARV infection.
3.5 Material and Methods
Animals, virus, and aerosol exposure
The samples used for these analyses were previously collected in a study by Lin et al (Lin
et al. 2015). Research was conducted under IACUC approved protocol in compliance with
the Animal Welfare Ace, PHS Policy, and other deferral statues and regulations relating
to animals and experiments involving animals. The facility where this research was con-
ducted is accredited by the Association for Assessment and Accreditation of Laboratory
Animal Care, International and adheres to principles stated in the Guide for the Care and
Use of Laboratory Animals. Briefly, 15 Rhesus macaques were obtained from World Wide
Primates (Miami, FL) and randomly assigned to sacrifice groups (N = 3; days 1, 3, 5, 7,
and 9 post-exposure). NHPs were acclimated to the BSL-4 laboratory prior to the begin-
ning of the study. At days -8 and -7, NHPs received a physical examination and baseline
parameters for hematology, serum chemistry, coagulation, and cytokine expression were
determined. On day 0, animals were exposed to a small particle aerosol dose of 1,000 PFU
of Marburg virus Angola (Marburg virus H. sapiens-tc/ANG/2005/Angola-1379c; Gen-
Bank: DQ447653.1) using the U.S. Army Medical Research Institute of Infectious Dis-
eases (USAMRIID) head-only automated bioaerosol exposure system (ABES-II). Starting
virus concentrations and exposure dose were confirmed by plaque assay (ibid.).
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Sample collection
Following euthanasia, a complete necropsy was performed on each animal in the BSL-4
laboratory. Blood collected at euthanasia and sera and PBMCs were isolated. Tissues were
collected and a portion was fixed in 10% neutral buffered formalin for a minimum of 21
days for pathological examination and another portion was snap frozen and homogenized
in Trizol LS for virus genome quantification and RNA sequencing. For this study, we
focused on the tracheobronchial, mesenteric, and inguinal lymph nodes. These samples
were removed from the BSL-4 laboratory upon sufficient inactivation in Trizol LS.
RNA sequencing
RNA was isolated from the lymph node samples using the PureLink RNA Mini kit (Thermo
Fisher Scientific). Libraries were generated on the Sciclone G3 liquid handling robot
(Perkin Elmer) using the TruSeq RNA Library Prep Kit v2 (Illumina). Library quality
was evaluated suing the DNA 1K Chip on the LabChipGX (Perkin Elmer) and quantified
by qPCR using the KAPA Complete qPCR kit for Illumina libraries (Kapa Biosystems).
Libraries were diluted to 10nM and cluster generation was performed on the Illumina cBot.
Libraries were sequenced on the HiSeq 2500 using a paired end 1x100bp, single index for-
mat.
RNA-seq analysis
Sequence quality filtering and adapter trimming was performed using TrimGalore
v0.3.7 (Trim Galore!) in paired-end mode with a quality phred score cutoff of
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20, a maximum trimming error rate of 0.1, and a minimum required adapter over-
lap of 1 (-f fastq -e 0.1 -q 20 -O 1). The adapter sequences AGATCGGAAGAG-
CACACGTCTGAACTCCAGTCAC and AGATCGGAAGAGCGTCGTGTAGGGAAA-
GAGTGTAGATCTCGGTGGTCGCCGTATCATT were used to trim adapters. After trim-
ming, each RNA-seq sample was checked for quality using fastQC v0.10.1 (FastQC) and
multiqc (v0.7) (Ewels et al. 2016) to aggregate the results. For gene expression quantifi-
cation, we used Kallisto v0.43.0 (Bray et al. 2015) to map the preprocessed reads to the
transcriptome reference sequences generated from the Macaca mulatta genome annotation
version the MacaM Rhesus Genome v7 (Zimin et al. 2014). The output from Kallisto
generated the estimated count and TPM (transcripts per million) for each transcript. To
transform the transcript level quantification to gene level expression, we chose to use the
isoform with the highest mean TPM across all samples to be the representative isoform
for gene level quantification. Finally, we excluded any sample that had less than 500000
mapped reads. A total of 6 samples were excluded from further analysis.
Viral Transcriptome Quantification
For viral transcriptome quantification, we mapped the RNA reads to MARV genome
(Lake Victoria marburgvirus strain Uganda 371Bat2007, complete genome (GenkBank:
FJ750958.1)) using Kallisto v0.43.0 (Bray et al. 2015). We summed the reads mapped to
individual genes in each sample to obtain a pooled estimate for viral load. We used the
resulting output for the MAGE pipeline and obtained the posterior for log2FC and baseline
expression.
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Global Gene Expression Analysis
Global gene expression analysis was performed by Principle component analysis(PCA)
using “prcomp” function in R. PCA was performed using the posterior Log2 fold change
for 13,918 genes as the input with scaling and centering.
Pathway Analysis
Ingenuity Pathway Analysis is used (Ingenuity Pathway Analysis, QIAGEN Inc.) for the
canonical pathway analysis. For the input of the pathway analysis, we used the differen-
tially expressed genes selected using 90%high density interval and the ROPE radius of 1.5.
We only considerd the pathways that has the p-value less than 0.05.
Unsupervised Clustering via Mapper
Since Mapper requires to provide the two tunable parameters, resolution and gain, we
performed the grid search on these parameters (Figure 3) in 3.5 and chose the parameter
set that maximizes the Dunn index (Dunn 1973) of the clustering in the resulting network




Where D corresponds to a distance function (max distance between members in two
clusters ci and c j), and m the number of clusters, and T corresponds to the intra distance
function. The clustering algorithm for a network, we used the community detection algo-
rithm based on edge betweenness (Girvan and Newman 2002). We used the “cluster-edge-
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betweenness” function from igraph in R (Csardi and Nepusz 2006). There were 8 singleton
nodes that did not have with any edge with other nodes. These singleton nodes contain 9
genes, which are BMP5, C19orf77, DNAJA4, FKBP4, IFNA4, KCTD19, KLKB1, OTX1,
and TMIGD1, and they are removed from the downstream analysis.
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Conclusion
In my thesis, I have discussed the three important components of the transcriptome analy-
sis and how they contributed to our understanding of Marburg virus infection and immune
responses in animal hosts. In the first of my thesis, I have presented the comprehensive
de novo reference transcriptome of Rousettus aegyptiacus. The challenge I addressed and
contribution I made is to come up with the reference transcriptome without genome se-
quences available. There I used an iterative approach to combine the individual assemblies
and performed homology-based annotation to obtain the transcript level annotation of pre-
viously uncharacterized Rousettus aegyptiacus transcriptome. I tested the transcriptome
against several metrics to show its validity and made biological remarks about the tran-
scriptome of Rousettus aegyptiacus. In the next chapter of my thesis, I delved into the
development of the statistical machinery combining the best practices of gene expression
analysis, Bayesian statistics, and multilevel modeling. I constructed the pipeline in which
the raw sequence input get transformed into the posterior MCMC samples. The model
implemented exploited the multilevel modeling structure of the data, resulting in regular-
ized estimates of parameters, with which users can make practical and useful inference
for biological questions. I showed that the model is valid, scalable, and useful for the
RNAseq experiments with the complex experimental designs. In the last part of my thesis,
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I employed MAGE pipeline to characterize the immune responses of the three lymph node
tissues of Macaca mulata infected MARV over the course of 9 days. The global expres-
sion pattern was the separation between early and late stages. Furthermore, I identified a
set of genes which are differentially expressed at each DPI compared to day 1 and inferred
the implicated pathways. I also identified the genes which are preferentially expressed in
TbLN and not in other Lymph nodes. Lastly, I clustered the genes into six groups in an
unsupervised manner using a topological method to capture the distinctive trends present
in the expression profile of lymph nodes of rhesuses infected with MARV. The pipeline
and references I developed and the findings I made with these tools will contribute to the
growing body of Marburg virus research and helping researchers in the field generate more
interesting biological questions and puzzles to tackle this deadly virus.
89
Bibliography
Adams, Mark D et al. (1991). “Complementary DNA sequencing: expressed sequence tags
and human genome project”. In: Science 252.5013, pp. 1651–1656.
Aken, Bronwen L et al. (2016). “The Ensembl gene annotation system”. In: Database 2016.
Alexa, Adrian and Jorg Rahnenfuhrer (2010). topGO: topGO: Enrichment analysis for
Gene Ontology. R package version 2.18.0.
Altschul, Stephen F et al. (1997). “Gapped BLAST and PSI-BLAST: a new generation of
protein database search programs”. In: Nucleic acids research 25.17, pp. 3389–3402.
Amman, Brian R et al. (2012). “Seasonal pulses of Marburg virus circulation in juvenile
Rousettus aegyptiacus bats coincide with periods of increased risk of human infection”.
In: PLoS pathogens 8.10, e1002877.
Amman, Brian R et al. (2015). “Oral shedding of Marburg virus in experimentally in-
fected Egyptian fruit bats (Rousettus Aegyptiacus)”. In: Journal of wildlife diseases
51.1, pp. 113–124.
Aryee, Martin J et al. (2009). “An improved empirical bayes approach to estimating differ-
ential gene expression in microarray time-course data: BETR (Bayesian Estimation of
Temporal Regulation)”. In: BMC bioinformatics 10.1, p. 409.
Ashburner, Michael et al. (2000). “Gene Ontology: tool for the unification of biology”. In:
Nature genetics 25.1, pp. 25–29.
Auer, Paul L and RW Doerge (2010). “Statistical design and analysis of RNA sequencing
data”. In: Genetics 185.2, pp. 405–416.
Bar-Joseph, Ziv, Anthony Gitter, and Itamar Simon (2012). “Studying and modelling dy-
namic biological processes using time-series gene expression data”. In: Nature reviews.
Genetics 13.8, p. 552.
Bar-Joseph, Ziv et al. (2003). “Continuous representations of time-series gene expression
data”. In: Journal of Computational Biology 10.3-4, pp. 341–356.
90
Barczak, Amy K et al. (2012). “RNA signatures allow rapid identification of pathogens
and antibiotic susceptibilities”. In: Proceedings of the National Academy of Sciences
109.16, pp. 6217–6222.
Bausch, Daniel G et al. (2006). “Marburg hemorrhagic fever associated with multiple ge-
netic lineages of virus”. In: New England Journal of Medicine 355.9, pp. 909–919.
Bean, Andrew GD et al. (2013). “Studying immunity to zoonotic diseases in the natural
host [mdash] keeping it real”. In: Nature Reviews Immunology 13.12, pp. 851–861.
Betancourt, Michael and Mark Girolami (2015). “Hamiltonian Monte Carlo for hierarchi-
cal models”. In: Current trends in Bayesian methodology with applications 79, p. 30.
Bolstad, Benjamin M et al. (2003). “A comparison of normalization methods for high den-
sity oligonucleotide array data based on variance and bias”. In: Bioinformatics 19.2,
pp. 185–193.
Bosio, Catharine M et al. (2003). “Ebola and Marburg viruses replicate in monocyte-
derived dendritic cells without inducing the production of cytokines and full matu-
ration”. In: The Journal of infectious diseases 188.11, pp. 1630–1638.
Brauburger, Kristina et al. (2012). “Forty-five years of Marburg virus research”. In: Viruses
4.10, pp. 1878–1927.
Brawand, David et al. (2011). “The evolution of gene expression levels in mammalian
organs”. In: Nature 478.7369, pp. 343–348.
Bray, Nicolas et al. (2015). “Near-optimal RNA-Seq quantification”. In: arXiv preprint
arXiv:1505.02710.
Brazma, Alvis et al. (2001). “Minimum information about a microarray experiment (MI-
AME)toward standards for microarray data”. In: Nature genetics 29.4, pp. 365–371.
Brooks, Stephen P and Andrew Gelman (1998). “General methods for monitoring conver-
gence of iterative simulations”. In: Journal of computational and graphical statistics
7.4, pp. 434–455.
Calisher, Charles H et al. (2006). “Bats: important reservoir hosts of emerging viruses”. In:
Clinical microbiology reviews 19.3, pp. 531–545.
Ca´mara, Pablo G (2017). “Topological methods for genomics: Present and future direc-
tions”. In: Current Opinion in Systems Biology 1, pp. 95–101.
Carlsson, Gunnar (2009). “Topology and data”. In: Bulletin of the American Mathematical
Society 46.2, pp. 255–308.
91
Carpenter, Bob et al. (2016). “Stan: A probabilistic programming language”. In: Journal of
Statistical Software 20, pp. 1–37.
Chang, Winston et al. (2017). shiny: Web Application Framework for R. R package version
1.0.3. URL: https://CRAN.R-project.org/package=shiny.
Chronology of Marburg Hemorrhagic Fever Outbreaks (2014). https://www.cdc.gov/
vhf/marburg/resources/outbreak-table.html. [Online; accessed 2017-08-21].
Chua, KB et al. (2000). “Nipah virus: a recently emergent deadly paramyxovirus”. In:
Science 288.5470, pp. 1432–1435.
Conesa, Ana et al. (2016). “A survey of best practices for RNA-seq data analysis”. In:
Genome biology 17.1, p. 13.
Connor, John H et al. (2015). “Transcriptional profiling of the immune response to Marburg
virus infection”. In: Journal of virology 89.19, pp. 9865–9874.
Csardi, Gabor and Tamas Nepusz (2006). “The igraph software package for complex net-
work research”. In: InterJournal Complex Systems, p. 1695. URL: http://igraph.
org.
Degexp, Degexp et al. (2010). “DEGseq”. In: 2.
Dobin, Alexander et al. (2013). “STAR: ultrafast universal RNA-seq aligner”. In: Bioinfor-
matics 29.1, pp. 15–21.
Duggan, David J et al. (1999). “Expression profiling using cDNA microarrays.” In: Nature
genetics 21.
Dunn, Joseph C (1973). “A fuzzy relative of the ISODATA process and its use in detecting
compact well-separated clusters”. In:
Ebrahimi-Fakhari, Darius et al. (2016). “Reduction of TMEM97 increases NPC1 protein
levels and restores cholesterol trafficking in Niemann-pick type C1 disease cells”. In:
Human molecular genetics 25.16, pp. 3588–3599.
Ewels, Philip et al. (2016). “MultiQC: summarize analysis results for multiple tools and
samples in a single report”. In: Bioinformatics 32.19, pp. 3047–3048.
FastQC. URL: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
Feldmann, H and MP Kiley (1999). “Classification, structure, and replication of
filoviruses.” In: Current topics in microbiology and immunology 235, p. 1.
92
Feldmann, Heinz and Thomas W Geisbert (2011). “Ebola haemorrhagic fever”. In: The
Lancet 377.9768, pp. 849–862.
Field, Hume, Brad McCall, and Janine Barrett (1999). “Australian bat lyssavirus infection
in a captive juvenile black flying fox.” In: Emerging infectious diseases 5.3, p. 438.
Friedman, Jerome, Trevor Hastie, and Robert Tibshirani (2001). The elements of statistical
learning. Vol. 1. Springer series in statistics New York.
Gear, Js S et al. (1975). “Outbreake of Marburg virus disease in Johannesburg.” In: Br Med
J 4.5995, pp. 489–493.
Geisbert, Thomas W et al. (2007). “Marburg virus Angola infection of rhesus macaques:
pathogenesis and treatment with recombinant nematode anticoagulant protein c2”. In:
The Journal of infectious diseases 196.Supplement 2, S372–S381.
Geisbert, Thomas W et al. (2008). “Vesicular stomatitis virus-based vaccines protect non-
human primates against aerosol challenge with Ebola and Marburg viruses”. In: Vaccine
26.52, pp. 6894–6900.
Geisbert, Thomas W et al. (2009). “Single-injection vaccine protects nonhuman primates
against infection with marburg virus and three species of ebola virus”. In: Journal of
virology 83.14, pp. 7296–7304.
Gelman, Andrew and Jennifer Hill (2007). Data analysis using regression and multilevel-
hierarchical models. Vol. 1. Cambridge University Press New York, NY, USA.
Gelman, Andrew and Donald B Rubin (1992). “Inference from iterative simulation using
multiple sequences”. In: Statistical science, pp. 457–472.
— (1995). “Avoiding model selection in Bayesian social research”. In: Sociological
methodology 25, pp. 165–173.
Gelman, Andrew et al. (2006). “Prior distributions for variance parameters in hierarchi-
cal models (comment on article by Browne and Draper)”. In: Bayesian analysis 1.3,
pp. 515–534.
Gelman, Andrew et al. (2014). Bayesian data analysis. Vol. 2. CRC press Boca Raton, FL.
Gibbs, Richard A et al. (2007). “Evolutionary and biomedical insights from the rhesus
macaque genome”. In: science 316.5822, pp. 222–234.
Girvan, Michelle and Mark EJ Newman (2002). “Community structure in social and
biological networks”. In: Proceedings of the national academy of sciences 99.12,
pp. 7821–7826.
93
Grabherr, Manfred G et al. (2011). “Full-length transcriptome assembly from RNA-Seq
data without a reference genome”. In: Nature biotechnology 29.7, pp. 644–652.
Groot, Raoul J de et al. (2013). “Middle East respiratory syndrome coronavirus (MERS-
CoV): announcement of the Coronavirus Study Group”. In: Journal of virology 87.14,
pp. 7790–7792.
Heinonen, Markus et al. (2014). “Detecting time periods of differential gene expression
using Gaussian processes: an application to endothelial cells exposed to radiotherapy
dose fraction”. In: Bioinformatics 31.5, pp. 728–735.
Hu, Zhi-Liang, Jie Bao, and James M Reecy (2008). “CateGOrizer: a web-based program
to batch analyze gene ontology classification categories”. In: Online Journal of Bioin-
formatics 9.2, pp. 108–112.
Ingenuity Pathway Analysis, QIAGEN Inc. URL: https : / / www .
qiagenbioinformatics.com/products/ingenuitypathway-analysis.
Johnson, ED et al. (1996). “Characterization of a new Marburg virus isolated from a 1987
fatal case in Kenya”. In: Archives of Virology Supplement, pp. 101–114.
Jones, Megan EB et al. (2015). “Experimental Inoculation of Egyptian Rousette Bats
(Rousettus aegyptiacus) with Viruses of the Ebolavirus and Marburgvirus Genera”. In:
Viruses 7.7, pp. 3420–3442.
Ke, Po-Yuan and Steve S-L Chen (2013). “Active RNA replication of hepatitis C virus
downregulates CD81 expression”. In: PloS one 8.1, e54866.
Kiley, MP et al. (1982). “Filoviridae: a taxonomic home for Marburg and Ebola viruses?”
In: Intervirology 18.1-2, pp. 24–32.
Kim, Daehwan, Ben Langmead, and Steven L Salzberg (2015). “HISAT: a fast spliced
aligner with low memory requirements”. In: Nature methods 12.4, pp. 357–360.
Kim, Daehwan et al. (2013). “TopHat2: accurate alignment of transcriptomes in the pres-
ence of insertions, deletions and gene fusions”. In: Genome biology 14.4, R36.
Kra¨mer, Andreas et al. (2013). “Causal analysis approaches in ingenuity pathway analysis”.
In: Bioinformatics 30.4, pp. 523–530.
Kruschke, John K (2013). “Bayesian estimation supersedes the t test.” In: Journal of Ex-
perimental Psychology: General 142.2, p. 573.
94
Kruschke, John K and Torrin M Liddell (2017). “The Bayesian New Statistics: Hypothesis
testing, estimation, meta-analysis, and power analysis from a Bayesian perspective”.
In: Psychonomic Bulletin & Review, pp. 1–29.
Kruschke, John (2014). Doing Bayesian data analysis: A tutorial with R, JAGS, and Stan.
Academic Press.
Kuhn, Jens H et al. (2010). “Proposal for a revised taxonomy of the family Filoviridae: clas-
sification, names of taxa and viruses, and virus abbreviations”. In: Archives of virology
155.12, pp. 2083–2103.
Law, Charity W et al. (2014). “voom : precision weights unlock linear model analysis tools
for RNA-seq read counts”. In: pp. 1–17.
Lee, Albert et al. (2014). “Transcriptome reconstruction and annotation of cynomolgus and
African green monkey”. In: BMC genomics 15.1, p. 846.
Leroy, Eric M et al. (2005). “Fruit bats as reservoirs of Ebola virus”. In: Nature 438.7068,
pp. 575–576.
Li, Bo and Colin N Dewey (2011). “RSEM: accurate transcript quantification from RNA-
Seq data with or without a reference genome”. In: BMC bioinformatics 12.1, p. 323.
Li, Weizhong and Adam Godzik (2006). “Cd-hit: a fast program for clustering and compar-
ing large sets of protein or nucleotide sequences”. In: Bioinformatics 22.13, pp. 1658–
1659.
Li, Wendong et al. (2005). “Bats are natural reservoirs of SARS-like coronaviruses”. In:
Science 310.5748, pp. 676–679.
Liang, Peng, Arthur B Pardee, et al. (1992). “Differential display of eukaryotic messenger
RNA by means of the polymerase chain reaction”. In: Science 257.5072, pp. 967–971.
Lin, Kenny L et al. (2015). “Temporal characterization of Marburg virus Angola infec-
tion following aerosol challenge in rhesus macaques”. In: Journal of virology 89.19,
pp. 9875–9885.
Love, Michael I, Wolfgang Huber, and Simon Anders (2014). “Moderated estimation of
fold change and dispersion for RNA-seq data with DESeq2”. In: pp. 1–21. DOI: 10.
1186/s13059-014-0550-8.
Lum, PY et al. (2013). “Extracting insights from the shape of complex data using topol-
ogy”. In: Scientific reports 3, p. 1236.
95
Martin, Marcel (2011). “Cutadapt removes adapter sequences from high-throughput se-
quencing reads”. In: EMBnet. journal 17.1, pp–10.
McCarthy et al. (2012). “Differential expression analysis of multifactor RNA-Seq exper-
iments with respect to biological variation”. In: Nucleic Acids Research 40.10, pp. –
9.
McElreath, Richard (2015). Statistical Rethinking. A Bayesian Course with Examples in R
and Stan. Chapman and HallCRC.
Middleton, DJ et al. (2007). “Experimental Nipah virus infection in pteropid bats (Pteropus
poliocephalus)”. In: Journal of comparative pathology 136.4, pp. 266–272.
Mohamadzadeh, Mansour, Lieping Chen, and Alan L Schmaljohn (2007). “How Ebola
and Marburg viruses battle the immune system”. In: Nature reviews. Immunology 7.7,
p. 556.
Moratelli, Ricardo and Charles H Calisher (2015). “Bats and zoonotic viruses: can we con-
fidently link bats with emerging deadly viruses?” In: Memorias do Instituto Oswaldo
Cruz 110.1, pp. 1–22.
Morens, David M, Gregory K Folkers, and Anthony S Fauci (2004). “The challenge of
emerging and re-emerging infectious diseases”. In: Nature 430.6996, p. 242.
Mortazavi, Ali et al. (2008). “Mapping and quantifying mammalian transcriptomes by
RNA-Seq”. In: Nature methods 5.7, pp. 621–628.
NCBI Eukaryotic genomes annotations. URL: http : / / www . ncbi . nlm . nih . gov /
genome/annotation\_euk/all/.
Nakayama, Eri and Masayuki Saijo (2013). “Animal models for Ebola and Marburg virus
infections”. In: Frontiers in microbiology 4.
Nelder, John Ashworth and R Jacob Baker (1972). Generalized linear models. Wiley On-
line Library.
Nikiforov, VV et al. (1993). “A case of a laboratory infection with Marburg fever”. In:
Zhurnal mikrobiologii, epidemiologii, i immunobiologii 3, pp. 104–106.
Nueda, Marı´a Jose´, Sonia Tarazona, and Ana Conesa (2014). “Next maSigPro: updating
maSigPro bioconductor package for RNA-seq time series”. In: Bioinformatics 30.18,
pp. 2598–2602.
96
O’Leary, Nuala A et al. (2015). “Reference sequence (RefSeq) database at NCBI: current
status, taxonomic expansion, and functional annotation”. In: Nucleic acids research
44.D1, pp. D733–D745.
Ogawa, Hirohito et al. (2015). “Seroepidemiological prevalence of multiple species of
filoviruses in fruit bats (Eidolon helvum) migrating in Africa”. In: Journal of Infec-
tious Diseases, jiv063.
Olival, Kevin J et al. (2013). “Ebola virus antibodies in fruit bats, Bangladesh”. In: Emerg-
ing infectious diseases 19.2, p. 270.
Omatsu, Tsutomu et al. (2008). “Induction and sequencing of Rousette bat interferon α
and β genes”. In: Veterinary immunology and immunopathology 124.1, pp. 169–176.
Oshlack, Alicia, Mark D Robinson, and Matthew D Young (2010). “From RNA-seq reads
to differential expression results”. In: Genome biology 11.12, p. 220.
Pan, Wei (2002). “A comparative review of statistical methods for discovering differen-
tially expressed genes in replicated microarray experiments”. In: Bioinformatics 18.4,
pp. 546–554.
Papenfuss, Anthony T et al. (2012). “The immune gene repertoire of an important viral
reservoir, the Australian black flying fox”. In: BMC genomics 13.1, p. 261.
Paweska, Janusz T et al. (2012). “Virological and serological findings in Rousettus aegypti-
acus experimentally inoculated with vero cells-adapted hogan strain of Marburg virus”.
In: PloS one 7.9, e45479.
Paweska, Janusz T et al. (2015). “Lack of Marburg Virus Transmission From Experimen-
tally Infected to Susceptible In-Contact Egyptian Fruit Bats”. In: Journal of Infectious
Diseases, jiv132.
Peng, Xinxia et al. (2014). “Tissue-specific transcriptome sequencing analysis expands the
non-human primate reference transcriptome resource (NHPRTR)”. In: Nucleic acids
research 43.D1, pp. D737–D742.
Pimentel, Harold et al. (2017). “Differential analysis of RNA-seq incorporating quantifica-
tion uncertainty”. In: Nature Publishing Group 14.7. ISSN: 1548-7091. DOI: 10.1038/
nmeth.4324. URL: http://dx.doi.org/10.1038/nmeth.4324.
Polson, Nicholas G, James G Scott, et al. (2012). “On the half-Cauchy prior for a global
scale parameter”. In: Bayesian Analysis 7.4, pp. 887–902.
97
Pourrut, Xavier et al. (2009). “Large serological survey showing cocirculation of Ebola
and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both
viruses in Rousettus aegyptiacus”. In: BMC infectious diseases 9.1, p. 159.
Quinlan, Aaron R and Ira M Hall (2010). “BEDTools: a flexible suite of utilities for com-
paring genomic features”. In: Bioinformatics 26.6, pp. 841–842.
R Core Team (2015). R: A Language and Environment for Statistical Computing. R Foun-
dation for Statistical Computing. Vienna, Austria. URL: http://www.R-project.
org/.
Rapaport, Franck et al. (2013). “Comprehensive evaluation of differential gene expression
analysis methods for RNA-seq data”. In: Genome biology 14.9, p. 3158.
Rizvi, Abbas H et al. (2017). “Single-cell topological RNA-seq analysis reveals insights
into cellular differentiation and development”. In: Nature Biotechnology 35.6, pp. 551–
560.
Robertson, Gordon et al. (2010). “De novo assembly and analysis of RNA-seq data”. In:
Nature methods 7.11, pp. 909–912.
Robinson, Mark D, Davis J McCarthy, and Gordon K Smyth (2010a). “edgeR: a Biocon-
ductor package for differential expression analysis of digital gene expression data”. In:
Bioinformatics 26.1, pp. 139–140.
— (2010b). “edgeR: a Bioconductor package for differential expression analysis of digital
gene expression data”. In: Bioinformatics 26, pp. –1.
Sae´z, Almudena Marı´ et al. (2015). “Investigating the zoonotic origin of the West African
Ebola epidemic”. In: EMBO molecular medicine 7.1, pp. 17–23.
Schena, Mark et al. (1995). “Quantitative monitoring of gene expression patterns with a
complementary DNA microarray”. In: SCIENCE-NEW YORK THEN WASHINGTON-,
pp. 467–467.
Seim, Inge et al. (2013). “Genome analysis reveals insights into physiology and longevity
of the Brandt’s bat Myotis brandtii”. In: Nature communications 4.
Shaw, Timothy I et al. (2012). “Transcriptome sequencing and annotation for the Jamaican
fruit bat (Artibeus jamaicensis)”. In: PloS one 7.11, e48472.
Siegert, Rudolf (1972). “Marburg virus”. In: Canine Distemper Virus. Springer, pp. 97–
153.
98
Singh, Gurjeet, Facundo Me´moli, and Gunnar E Carlsson (2007). “Topological methods
for the analysis of high dimensional data sets and 3d object recognition.” In: SPBG,
pp. 91–100.
Slenczka, Werner and Hans Dieter Klenk (2007). “Forty years of Marburg virus”. In: The
Journal of infectious diseases 196.Supplement 2, S131–S135.
Smith, DH et al. (1982). “Marburg-virus disease in Kenya”. In: The Lancet 319.8276,
pp. 816–820.
Smith, Ina et al. (2011). “Identifying Hendra virus diversity in pteropid bats”. In: PLoS
One 6.9, e25275.
Smyth, Gordon K (2005). “Limma: linear models for microarray data”. In: Bioinformatics
and computational biology solutions using R and Bioconductor. Springer, pp. 397–420.
Spies, Daniel and Constance Ciaudo (2015). “Dynamics in transcriptomics: advancements
in RNA-seq time course and downstream analysis”. In: Computational and structural
biotechnology journal 13, pp. 469–477.
Storey, John D et al. (2005). “Significance analysis of time course microarray experiments”.
In: Proceedings of the National Academy of Sciences of the United States of America
102.36, pp. 12837–12842.
Subramanian, Aravind et al. (2005). “Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles”. In: Proceedings of the Na-
tional Academy of Sciences 102.43, pp. 15545–15550.
Sun, Xiaoxiao et al. (2016). “Statistical inference for time course RNA-Seq data using a
negative binomial mixed-effect model”. In: BMC bioinformatics 17.1, p. 324.
Swanepoel, Robert et al. (1996). “Experimental inoculation of plants and animals with
Ebola virus.” In: Emerging infectious diseases 2.4, p. 321.
Swanepoel, Robert et al. (2007). “Studies of reservoir hosts for Marburg virus”. In: Emerg-
ing infectious diseases 13.12, p. 1847.
Teeling, Emma C et al. (2002). “Microbat paraphyly and the convergent evolution of a
key innovation in Old World rhinolophoid microbats”. In: Proceedings of the National
Academy of Sciences 99.3, pp. 1431–1436.
Towner, Jonathan S et al. (2006). “Marburgvirus genomics and association with a large
hemorrhagic fever outbreak in Angola”. In: Journal of virology 80.13, pp. 6497–6516.
99
Towner, Jonathan S et al. (2007). “Marburg virus infection detected in a common African
bat”. In: PLoS One 2.8, e764.
Towner, Jonathan S et al. (2009). “Isolation of genetically diverse Marburg viruses from
Egyptian fruit bats”. In: PLoS pathogens 5.7, e1000536.
TransDecoder. URL: https://transdecoder.github.io/.
Trim Galore! URL: https://www.bioinformatics.babraham.ac.uk/projects/
trim_galore/.
Van’t Veer, Laura J et al. (2002). “Gene expression profiling predicts clinical outcome of
breast cancer”. In: nature 415.6871, pp. 530–536.
Vehtari, Aki, Andrew Gelman, and Jonah Gabry (2017). “Practical Bayesian model eval-
uation using leave-one-out cross-validation and WAIC”. In: Statistics and Computing
27.5, pp. 1413–1432.
Velculescu, Victor E et al. (1995). “Serial analysis of gene expression”. In: Science
270.5235, p. 484.
Wang, Zhong, Mark Gerstein, and Michael Snyder (2009). “RNA-Seq: a revolutionary tool
for transcriptomics”. In: Nature reviews genetics 10.1, pp. 57–63.
Watson, Andrew et al. (1998). “Technology for microarray analysis of gene expression”.
In: Current opinion in biotechnology 9.6, pp. 609–614.
White, Judith M and Kathryn L Schornberg (2012). “A new player in the puzzle of filovirus
entry”. In: Nature Reviews Microbiology 10.5, pp. 317–322.
Wikipedia (2004). Cell Theory. [Online; accessed 2017-10-18]. URL: Celltheory.
Williamson, MM et al. (1998). “Transmission studies of Hendra virus (equine morbilli-
virus) in fruit bats, horses and cats”. In: Australian Veterinary Journal 76.12, pp. 813–
818.
Williamson, MM et al. (2000). “Experimental hendra virus infectionin pregnant guinea-
pigs and fruit Bats (Pteropus poliocephalus)”. In: Journal of Comparative Pathology
122.2, pp. 201–207.
Wilson, Don E and DeeAnn M Reeder (2005). Mammal species of the world: a taxonomic
and geographic reference. Baltimore: Johns Hopkins University Press.
Ye, Jian et al. (2012). “Primer-BLAST: a tool to design target-specific primers for poly-
merase chain reaction”. In: BMC bioinformatics 13.1, p. 134.
100
Ye, Shui Qing et al. (2002). “Microarray, SAGE and their applications to cardiovascular
diseases”. In: Cell research 12.2, pp. 105–115.
Young, Peter L et al. (1996). “Serologic evidence for the presence in Pteropus bats of a
paramyxovirus related to equine morbillivirus.” In: Emerging infectious diseases 2.3,
p. 239.
Yu, Guangchuang and Qing-Yu He (2016). “ReactomePA: an R/Bioconductor package for
reactome pathway analysis and visualization”. In: Molecular BioSystems 12.2, pp. 477–
479.
Zhang, Guojie et al. (2013). “Comparative analysis of bat genomes provides insight into
the evolution of flight and immunity”. In: Science 339.6118, pp. 456–460.
Zimin, Aleksey V et al. (2014). “A new rhesus macaque assembly and annotation for next-
generation sequencing analyses”. In: Biol Direct 9, p. 20.
101
Appendix
Chapter 1 Supplementary Table 1 - Tissue Specific Gene Ontology
Terms
Tissue GO.ID Term Annotated Significant Expected P-Value
BM GO:0002376 immune system process 2007.00 53.00 22.44 0.00
BM GO:0009611 response to wounding 883.00 30.00 9.87 0.00
BM GO:0050832 defense response to fungus 15.00 5.00 0.17 0.00
BM GO:0007596 blood coagulation 490.00 19.00 5.48 0.00
BM GO:0050817 coagulation 492.00 19.00 5.50 0.00
BM GO:0007599 hemostasis 495.00 19.00 5.54 0.00
BM GO:0050878 regulation of body fluid levels 608.00 21.00 6.80 0.00
BM GO:0042060 wound healing 627.00 21.00 7.01 0.00
BM GO:0007155 cell adhesion 959.00 27.00 10.72 0.00
BM GO:0022610 biological adhesion 963.00 27.00 10.77 0.00
BR GO:0007268 synaptic transmission 712.00 49.00 8.02 0.00
BR GO:0007267 cell-cell signaling 1122.00 54.00 12.63 0.00
BR GO:0050804 regulation of synaptic transmission 224.00 22.00 2.52 0.00
BR GO:0007399 nervous system development 1811.00 58.00 20.39 0.00
BR GO:0006836 neurotransmitter transport 180.00 19.00 2.03 0.00
BR GO:0001505 regulation of neurotransmitter levels 181.00 19.00 2.04 0.00
BR GO:0048489 synaptic vesicle transport 119.00 16.00 1.34 0.00
BR GO:0097480 establishment of synaptic vesicle locali... 119.00 16.00 1.34 0.00
BR GO:0097479 synaptic vesicle localization 121.00 16.00 1.36 0.00
BR GO:0031175 neuron projection development 772.00 35.00 8.69 0.00
HT GO:0003012 muscle system process 322.00 39.00 3.62 0.00
HT GO:0006936 muscle contraction 275.00 36.00 3.10 0.00
HT GO:0060047 heart contraction 165.00 30.00 1.86 0.00
HT GO:0003015 heart process 166.00 30.00 1.87 0.00
HT GO:0061061 muscle structure development 496.00 42.00 5.58 0.00
HT GO:0048738 cardiac muscle tissue development 155.00 27.00 1.74 0.00
HT GO:0008016 regulation of heart contraction 139.00 26.00 1.56 0.00
HT GO:0060537 muscle tissue development 319.00 34.00 3.59 0.00
HT GO:0014706 striated muscle tissue development 307.00 33.00 3.46 0.00
HT GO:0055002 striated muscle cell development 150.00 25.00 1.69 0.00
KY GO:0055085 transmembrane transport 1125.00 47.00 13.34 0.00
KY GO:0006811 ion transport 1282.00 50.00 15.20 0.00
KY GO:0006820 anion transport 465.00 27.00 5.51 0.00
KY GO:0007588 excretion 58.00 10.00 0.69 0.00
KY GO:0001822 kidney development 236.00 17.00 2.80 0.00
KY GO:0006814 sodium ion transport 182.00 15.00 2.16 0.00
KY GO:0034220 ion transmembrane transport 767.00 30.00 9.09 0.00
KY GO:0015711 organic anion transport 353.00 20.00 4.18 0.00
KY GO:0072001 renal system development 251.00 17.00 2.98 0.00
KY GO:0001655 urogenital system development 286.00 18.00 3.39 0.00
LG GO:0045333 cellular respiration 150.00 11.00 1.69 0.00
LG GO:0022904 respiratory electron transport chain 99.00 9.00 1.11 0.00
LG GO:0022900 electron transport chain 100.00 9.00 1.13 0.00
LG GO:0001944 vasculature development 528.00 20.00 5.94 0.00
LG GO:0072001 renal system development 251.00 13.00 2.83 0.00
LG GO:0006120 mitochondrial electron transport, NADH t... 42.00 6.00 0.47 0.00
LG GO:0048514 blood vessel morphogenesis 449.00 17.00 5.05 0.00
LG GO:0001822 kidney development 236.00 12.00 2.66 0.00
LG GO:0001568 blood vessel development 510.00 18.00 5.74 0.00
LG GO:0042773 ATP synthesis coupled electron transport 50.00 6.00 0.56 0.00
LN GO:0046649 lymphocyte activation 491.00 27.00 5.23 0.00
LN GO:0045321 leukocyte activation 581.00 29.00 6.19 0.00
LN GO:0001775 cell activation 800.00 31.00 8.53 0.00
LN GO:0031295 T cell costimulation 58.00 10.00 0.62 0.00
LN GO:0031294 lymphocyte costimulation 59.00 10.00 0.63 0.00
LN GO:0002376 immune system process 2007.00 50.00 21.40 0.00
LN GO:0002682 regulation of immune system process 1037.00 34.00 11.06 0.00
LN GO:0002694 regulation of leukocyte activation 337.00 19.00 3.59 0.00
LN GO:0042110 T cell activation 352.00 19.00 3.75 0.00
LN GO:0050865 regulation of cell activation 367.00 19.00 3.91 0.00
LV GO:1901605 alpha-amino acid metabolic process 200.00 25.00 2.07 0.00
LV GO:0019752 carboxylic acid metabolic process 871.00 41.00 9.03 0.00
LV GO:0043436 oxoacid metabolic process 977.00 43.00 10.12 0.00
LV GO:0006082 organic acid metabolic process 994.00 43.00 10.30 0.00
LV GO:0006520 cellular amino acid metabolic process 429.00 29.00 4.45 0.00
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LV GO:0009063 cellular amino acid catabolic process 105.00 17.00 1.09 0.00
LV GO:1901606 alpha-amino acid catabolic process 82.00 15.00 0.85 0.00
LV GO:0044282 small molecule catabolic process 242.00 21.00 2.51 0.00
LV GO:0055114 oxidation-reduction process 878.00 37.00 9.10 0.00
LV GO:0016054 organic acid catabolic process 191.00 19.00 1.98 0.00
OV GO:0007018 microtubule-based movement 187.00 13.00 1.59 0.00
OV GO:0022414 reproductive process 976.00 28.00 8.30 0.00
OV GO:0008406 gonad development 172.00 12.00 1.46 0.00
OV GO:0008584 male gonad development 108.00 10.00 0.92 0.00
OV GO:0046546 development of primary male sexual chara... 108.00 10.00 0.92 0.00
OV GO:0045137 development of primary sexual characteri... 177.00 12.00 1.50 0.00
OV GO:0008585 female gonad development 85.00 9.00 0.72 0.00
OV GO:0046545 development of primary female sexual cha... 89.00 9.00 0.76 0.00
OV GO:0044702 single organism reproductive process 878.00 25.00 7.46 0.00
OV GO:0044703 multi-organism reproductive process 707.00 22.00 6.01 0.00
PB GO:0007155 cell adhesion 959.00 48.00 11.58 0.00
PB GO:0022610 biological adhesion 963.00 48.00 11.63 0.00
PB GO:0006935 chemotaxis 616.00 37.00 7.44 0.00
PB GO:0042330 taxis 616.00 37.00 7.44 0.00
PB GO:0030198 extracellular matrix organization 354.00 25.00 4.28 0.00
PB GO:0043062 extracellular structure organization 355.00 25.00 4.29 0.00
PB GO:0006928 cellular component movement 1562.00 52.00 18.87 0.00
PB GO:0009605 response to external stimulus 1782.00 56.00 21.52 0.00
PB GO:0040011 locomotion 1412.00 49.00 17.05 0.00
PB GO:0050896 response to stimulus 6462.00 120.00 78.05 0.00
SP GO:0019752 carboxylic acid metabolic process 871.00 43.00 10.91 0.00
SP GO:0043436 oxoacid metabolic process 977.00 43.00 12.24 0.00
SP GO:0006082 organic acid metabolic process 994.00 43.00 12.45 0.00
SP GO:0055114 oxidation-reduction process 878.00 40.00 11.00 0.00
SP GO:0009063 cellular amino acid catabolic process 105.00 15.00 1.32 0.00
SP GO:0044282 small molecule catabolic process 242.00 20.00 3.03 0.00
SP GO:0016054 organic acid catabolic process 191.00 18.00 2.39 0.00
SP GO:0046395 carboxylic acid catabolic process 191.00 18.00 2.39 0.00
SP GO:0044281 small molecule metabolic process 2563.00 67.00 32.10 0.00
SP GO:0006520 cellular amino acid metabolic process 429.00 23.00 5.37 0.00
TT GO:0046661 male sex differentiation 133.00 13.00 1.24 0.00
TT GO:0022414 reproductive process 976.00 31.00 9.10 0.00
TT GO:0007548 sex differentiation 227.00 15.00 2.12 0.00
TT GO:0008584 male gonad development 108.00 11.00 1.01 0.00
TT GO:0046546 development of primary male sexual chara... 108.00 11.00 1.01 0.00
TT GO:0045137 development of primary sexual characteri... 177.00 13.00 1.65 0.00
TT GO:0032501 multicellular organismal process 5406.00 81.00 50.38 0.00
TT GO:0044702 single organism reproductive process 878.00 27.00 8.18 0.00
TT GO:0007283 spermatogenesis 360.00 17.00 3.35 0.00
TT GO:0048232 male gamete generation 361.00 17.00 3.36 0.00
Table 1: Enriched Biological Processes in Tissues
103
Tissue GO.ID Term Annotated Significant Expected P-Value
BM GO:0050786 RAGE receptor binding 10.00 4.00 0.11 0.00
BM GO:0001047 core promoter binding 117.00 8.00 1.29 0.00
BM GO:0000979 RNA polymerase II core promoter sequence... 44.00 5.00 0.49 0.00
BM GO:0001046 core promoter sequence-specific DNA bind... 75.00 6.00 0.83 0.00
BM GO:0005518 collagen binding 57.00 5.00 0.63 0.00
BM GO:0042802 identical protein binding 1010.00 23.00 11.15 0.00
BM GO:0042803 protein homodimerization activity 587.00 16.00 6.48 0.00
BM GO:0008301 DNA binding, bending 17.00 3.00 0.19 0.00
BM GO:0050840 extracellular matrix binding 44.00 4.00 0.49 0.00
BM GO:0005504 fatty acid binding 23.00 3.00 0.25 0.00
BR GO:0005215 transporter activity 1081.00 31.00 11.21 0.00
BR GO:0005216 ion channel activity 342.00 15.00 3.55 0.00
BR GO:0022838 substrate-specific channel activity 353.00 15.00 3.66 0.00
BR GO:0046873 metal ion transmembrane transporter acti... 363.00 15.00 3.76 0.00
BR GO:0015267 channel activity 370.00 15.00 3.84 0.00
BR GO:0022803 passive transmembrane transporter activi... 370.00 15.00 3.84 0.00
BR GO:0022836 gated channel activity 281.00 13.00 2.91 0.00
BR GO:0022843 voltage-gated cation channel activity 133.00 9.00 1.38 0.00
BR GO:0022890 inorganic cation transmembrane transport... 435.00 16.00 4.51 0.00
BR GO:0015075 ion transmembrane transporter activity 708.00 21.00 7.34 0.00
HT GO:0008092 cytoskeletal protein binding 742.00 36.00 7.97 0.00
HT GO:0008307 structural constituent of muscle 41.00 11.00 0.44 0.00
HT GO:0003779 actin binding 366.00 24.00 3.93 0.00
HT GO:0044325 ion channel binding 76.00 10.00 0.82 0.00
HT GO:0042805 actinin binding 26.00 7.00 0.28 0.00
HT GO:0005198 structural molecule activity 520.00 22.00 5.59 0.00
HT GO:0051393 alpha-actinin binding 22.00 6.00 0.24 0.00
HT GO:0031432 titin binding 12.00 5.00 0.13 0.00
HT GO:0032036 myosin heavy chain binding 10.00 3.00 0.11 0.00
HT GO:0048037 cofactor binding 241.00 10.00 2.59 0.00
KY GO:0015291 secondary active transmembrane transport... 180.00 24.00 2.16 0.00
KY GO:0022857 transmembrane transporter activity 821.00 43.00 9.86 0.00
KY GO:0022891 substrate-specific transmembrane transpo... 756.00 41.00 9.08 0.00
KY GO:0022804 active transmembrane transporter activit... 278.00 26.00 3.34 0.00
KY GO:0015075 ion transmembrane transporter activity 708.00 39.00 8.51 0.00
KY GO:0005215 transporter activity 1081.00 47.00 12.99 0.00
KY GO:0008509 anion transmembrane transporter activity 246.00 23.00 2.96 0.00
KY GO:0022892 substrate-specific transporter activity 894.00 41.00 10.74 0.00
KY GO:0015293 symporter activity 124.00 16.00 1.49 0.00
KY GO:0008514 organic anion transmembrane transporter ... 147.00 17.00 1.77 0.00
LG GO:0003954 NADH dehydrogenase activity 38.00 7.00 0.42 0.00
LG GO:0008137 NADH dehydrogenase (ubiquinone) activity 38.00 7.00 0.42 0.00
LG GO:0050136 NADH dehydrogenase (quinone) activity 38.00 7.00 0.42 0.00
LG GO:0016651 oxidoreductase activity, acting on NAD(P... 81.00 9.00 0.89 0.00
LG GO:0016655 oxidoreductase activity, acting on NAD(P... 49.00 7.00 0.54 0.00
LG GO:0022857 transmembrane transporter activity 821.00 22.00 9.01 0.00
LG GO:0005215 transporter activity 1081.00 25.00 11.86 0.00
LG GO:0022892 substrate-specific transporter activity 894.00 21.00 9.81 0.00
LG GO:0005178 integrin binding 101.00 6.00 1.11 0.00
LG GO:0051183 vitamin transporter activity 18.00 3.00 0.20 0.00
LN GO:0004872 receptor activity 958.00 23.00 9.44 0.00
LN GO:0005102 receptor binding 1140.00 25.00 11.23 0.00
LN GO:0016614 oxidoreductase activity, acting on CH-OH... 98.00 6.00 0.97 0.00
LN GO:0004888 transmembrane signaling receptor activit... 670.00 16.00 6.60 0.00
LN GO:0003823 antigen binding 48.00 4.00 0.47 0.00
LN GO:0038023 signaling receptor activity 762.00 17.00 7.51 0.00
LN GO:0050839 cell adhesion molecule binding 167.00 7.00 1.64 0.00
LN GO:0005178 integrin binding 101.00 5.00 0.99 0.00
LN GO:0008009 chemokine activity 32.00 3.00 0.32 0.00
LN GO:0005283 sodium:amino acid symporter activity 10.00 2.00 0.10 0.00
LV GO:0016491 oxidoreductase activity 575.00 24.00 5.75 0.00
LV GO:0005319 lipid transporter activity 81.00 9.00 0.81 0.00
LV GO:0008236 serine-type peptidase activity 141.00 11.00 1.41 0.00
LV GO:0016645 oxidoreductase activity, acting on the C... 26.00 6.00 0.26 0.00
LV GO:0017171 serine hydrolase activity 143.00 11.00 1.43 0.00
LV GO:0004252 serine-type endopeptidase activity 121.00 10.00 1.21 0.00
LV GO:0005215 transporter activity 1081.00 28.00 10.81 0.00
LV GO:0048037 cofactor binding 241.00 12.00 2.41 0.00
LV GO:0003824 catalytic activity 4858.00 74.00 48.57 0.00
LV GO:0019842 vitamin binding 72.00 7.00 0.72 0.00
OV GO:0003777 microtubule motor activity 75.00 11.00 0.66 0.00
OV GO:0003774 motor activity 124.00 11.00 1.09 0.00
OV GO:0005509 calcium ion binding 571.00 14.00 5.03 0.00
OV GO:0016887 ATPase activity 367.00 10.00 3.23 0.00
OV GO:0005201 extracellular matrix structural constitu... 64.00 4.00 0.56 0.00
OV GO:0004867 serine-type endopeptidase inhibitor acti... 72.00 4.00 0.63 0.00
OV GO:0005198 structural molecule activity 520.00 11.00 4.58 0.01
OV GO:0005160 transforming growth factor beta receptor... 44.00 3.00 0.39 0.01
OV GO:0043565 sequence-specific DNA binding 681.00 13.00 6.00 0.01
OV GO:0017111 nucleoside-triphosphatase activity 698.00 12.00 6.15 0.02
PB GO:0004872 receptor activity 958.00 35.00 11.51 0.00
PB GO:0038023 signaling receptor activity 762.00 29.00 9.15 0.00
PB GO:0004888 transmembrane signaling receptor activit... 670.00 26.00 8.05 0.00
PB GO:0005201 extracellular matrix structural constitu... 64.00 8.00 0.77 0.00
PB GO:0005509 calcium ion binding 571.00 20.00 6.86 0.00
PB GO:0004871 signal transducer activity 1076.00 29.00 12.93 0.00
PB GO:0060089 molecular transducer activity 1076.00 29.00 12.93 0.00
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PB GO:0003779 actin binding 366.00 15.00 4.40 0.00
PB GO:0019838 growth factor binding 107.00 8.00 1.29 0.00
PB GO:0005518 collagen binding 57.00 6.00 0.68 0.00
SP GO:0016491 oxidoreductase activity 575.00 30.00 6.78 0.00
SP GO:0003824 catalytic activity 4858.00 94.00 57.27 0.00
SP GO:0016655 oxidoreductase activity, acting on NAD(P... 49.00 9.00 0.58 0.00
SP GO:0003954 NADH dehydrogenase activity 38.00 8.00 0.45 0.00
SP GO:0008137 NADH dehydrogenase (ubiquinone) activity 38.00 8.00 0.45 0.00
SP GO:0050136 NADH dehydrogenase (quinone) activity 38.00 8.00 0.45 0.00
SP GO:0016651 oxidoreductase activity, acting on NAD(P... 81.00 10.00 0.95 0.00
SP GO:0048037 cofactor binding 241.00 15.00 2.84 0.00
SP GO:0031406 carboxylic acid binding 172.00 11.00 2.03 0.00
SP GO:0043177 organic acid binding 173.00 11.00 2.04 0.00
TT GO:0046983 protein dimerization activity 902.00 20.00 8.28 0.00
TT GO:0004871 signal transducer activity 1076.00 21.00 9.88 0.00
TT GO:0060089 molecular transducer activity 1076.00 21.00 9.88 0.00
TT GO:0042803 protein homodimerization activity 587.00 14.00 5.39 0.00
TT GO:0008528 G-protein coupled peptide receptor activ... 97.00 5.00 0.89 0.00
TT GO:0001653 peptide receptor activity 99.00 5.00 0.91 0.00
TT GO:0004872 receptor activity 958.00 17.00 8.79 0.01
TT GO:0003705 RNA polymerase II distal enhancer sequen... 81.00 4.00 0.74 0.01
TT GO:0010181 FMN binding 14.00 2.00 0.13 0.01
TT GO:0090079 translation regulator activity, nucleic ... 14.00 2.00 0.13 0.01
Table 2: Enriched Molecular Functions in Tissues
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Tissue GO.ID Term Annotated Significant Expected P-Value
BM GO:0071944 cell periphery 3877.00 70.00 43.51 4.1E-6
BM GO:0031226 intrinsic component of plasma membrane 1234.00 31.00 13.85 1.5E-5
BM GO:0005886 plasma membrane 3800.00 67.00 42.64 1.9E-5
BM GO:0005887 integral component of plasma membrane 1193.00 30.00 13.39 2.0E-5
BM GO:0005576 extracellular region 3559.00 63.00 39.94 3.6E-5
BM GO:0044459 plasma membrane part 2030.00 42.00 22.78 4.1E-5
BM GO:0044421 extracellular region part 3122.00 56.00 35.03 9.0E-5
BM GO:0032587 ruffle membrane 75.00 6.00 0.84 1.9E-4
BM GO:0043230 extracellular organelle 2385.00 44.00 26.76 3.8E-4
BM GO:0065010 extracellular membrane-bounded organelle 2385.00 44.00 26.76 3.8E-4
BR GO:0045202 synapse 537.00 38.00 6.18 6.6E-20
BR GO:0097458 neuron part 896.00 45.00 10.31 1.0E-17
BR GO:0044456 synapse part 396.00 31.00 4.56 1.6E-17
BR GO:0043005 neuron projection 739.00 40.00 8.50 7.9E-17
BR GO:0030424 axon 300.00 22.00 3.45 4.2E-12
BR GO:0008021 synaptic vesicle 116.00 14.00 1.33 5.9E-11
BR GO:0042995 cell projection 1436.00 45.00 16.52 2.1E-10
BR GO:0005886 plasma membrane 3800.00 80.00 43.72 8.7E-10
BR GO:0071944 cell periphery 3877.00 80.00 44.61 2.4E-9
BR GO:0048786 presynaptic active zone 24.00 7.00 0.28 6.8E-9
HT GO:0030016 myofibril 189.00 44.00 2.11 < 1e-30
HT GO:0030017 sarcomere 170.00 42.00 1.90 < 1e-30
HT GO:0043292 contractile fiber 200.00 44.00 2.23 < 1e-30
HT GO:0044449 contractile fiber part 185.00 42.00 2.06 < 1e-30
HT GO:0031674 I band 115.00 30.00 1.28 < 1e-30
HT GO:0030018 Z disc 103.00 28.00 1.15 < 1e-30
HT GO:0015629 actin cytoskeleton 407.00 27.00 4.54 6.2E-14
HT GO:0016528 sarcoplasm 62.00 12.00 0.69 3.2E-12
HT GO:0031672 A band 30.00 9.00 0.33 2.5E-11
HT GO:0036379 myofilament 24.00 8.00 0.27 1.2E-10
KY GO:0098590 plasma membrane region 395.00 35.00 4.69 4.9E-21
KY GO:0016324 apical plasma membrane 229.00 25.00 2.72 2.3E-17
KY GO:0045177 apical part of cell 303.00 27.00 3.59 2.1E-16
KY GO:0043230 extracellular organelle 2385.00 72.00 28.29 1.3E-15
KY GO:0065010 extracellular membrane-bounded organelle 2385.00 72.00 28.29 1.3E-15
KY GO:0070062 extracellular vesicular exosome 2385.00 72.00 28.29 1.3E-15
KY GO:0005903 brush border 65.00 14.00 0.77 2.3E-14
KY GO:0044421 extracellular region part 3122.00 78.00 37.03 1.6E-12
KY GO:0016323 basolateral plasma membrane 175.00 18.00 2.08 2.5E-12
KY GO:0005576 extracellular region 3559.00 83.00 42.21 7.8E-12
LG GO:0005576 extracellular region 3559.00 78.00 40.19 7.5E-11
LG GO:0044421 extracellular region part 3122.00 71.00 35.26 2.1E-10
LG GO:0031226 intrinsic component of plasma membrane 1234.00 36.00 13.94 8.3E-8
LG GO:0043230 extracellular organelle 2385.00 54.00 26.93 1.3E-7
LG GO:0065010 extracellular membrane-bounded organelle 2385.00 54.00 26.93 1.3E-7
LG GO:0070062 extracellular vesicular exosome 2385.00 54.00 26.93 1.3E-7
LG GO:0031988 membrane-bounded vesicle 3025.00 63.00 34.16 1.4E-7
LG GO:0031982 vesicle 3122.00 64.00 35.26 1.9E-7
LG GO:0005747 mitochondrial respiratory chain complex ... 41.00 7.00 0.46 3.3E-7
LG GO:0030964 NADH dehydrogenase complex 41.00 7.00 0.46 3.3E-7
LN GO:0009897 external side of plasma membrane 199.00 15.00 2.01 1.5E-9
LN GO:0071944 cell periphery 3877.00 71.00 39.10 9.8E-9
LN GO:0098552 side of membrane 271.00 15.00 2.73 9.5E-8
LN GO:0044459 plasma membrane part 2030.00 45.00 20.47 1.1E-7
LN GO:0005886 plasma membrane 3800.00 67.00 38.32 1.9E-7
LN GO:0005576 extracellular region 3559.00 64.00 35.89 2.2E-7
LN GO:0001772 immunological synapse 29.00 5.00 0.29 9.5E-6
LN GO:0044421 extracellular region part 3122.00 54.00 31.49 1.2E-5
LN GO:0044425 membrane part 5144.00 76.00 51.88 2.5E-5
LN GO:0009986 cell surface 604.00 18.00 6.09 3.6E-5
LV GO:0005576 extracellular region 3559.00 73.00 36.15 2.8E-11
LV GO:0044421 extracellular region part 3122.00 65.00 31.71 4.8E-10
LV GO:0043230 extracellular organelle 2385.00 55.00 24.22 5.9E-10
LV GO:0065010 extracellular membrane-bounded organelle 2385.00 55.00 24.22 5.9E-10
LV GO:0070062 extracellular vesicular exosome 2385.00 55.00 24.22 5.9E-10
LV GO:0031988 membrane-bounded vesicle 3025.00 57.00 30.72 4.4E-7
LV GO:0031982 vesicle 3122.00 57.00 31.71 1.3E-6
LV GO:0005615 extracellular space 972.00 26.00 9.87 4.6E-6
LV GO:0016323 basolateral plasma membrane 175.00 10.00 1.78 1.2E-5
LV GO:0072562 blood microparticle 92.00 7.00 0.93 4.1E-5
OV GO:0005929 cilium 360.00 28.00 3.14 3.9E-19
OV GO:0030286 dynein complex 39.00 11.00 0.34 2E-14
OV GO:0005930 axoneme 66.00 12.00 0.58 3.8E-13
OV GO:0097014 ciliary cytoplasm 66.00 12.00 0.58 3.8E-13
OV GO:0032838 cell projection cytoplasm 82.00 12.00 0.72 5.7E-12
OV GO:0042995 cell projection 1436.00 40.00 12.54 1.1E-11
OV GO:0005858 axonemal dynein complex 12.00 6.00 0.10 3.4E-10
OV GO:0044447 axoneme part 23.00 7.00 0.20 7.1E-10
OV GO:0005868 cytoplasmic dynein complex 26.00 7.00 0.23 1.9E-9
OV GO:0044441 ciliary part 238.00 14.00 2.08 2E-8
PB GO:0031012 extracellular matrix 367.00 26.00 4.35 1.9E-13
PB GO:0071944 cell periphery 3877.00 90.00 45.98 4.7E-13
PB GO:0005578 proteinaceous extracellular matrix 306.00 23.00 3.63 1.6E-12
PB GO:0005886 plasma membrane 3800.00 85.00 45.07 3.5E-11
PB GO:0044420 extracellular matrix part 119.00 14.00 1.41 1.2E-10
PB GO:0009897 external side of plasma membrane 199.00 16.00 2.36 1.8E-9
PB GO:0009986 cell surface 604.00 27.00 7.16 2.4E-9
PB GO:0044459 plasma membrane part 2030.00 54.00 24.08 3E-9
PB GO:0098552 side of membrane 271.00 18.00 3.21 3.4E-9
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PB GO:0005576 extracellular region 3559.00 75.00 42.21 2.4E-8
SP GO:0005739 mitochondrion 1419.00 57.00 17.44 1.2E-16
SP GO:0005576 extracellular region 3559.00 92.00 43.73 2.9E-15
SP GO:0044421 extracellular region part 3122.00 82.00 38.36 1.6E-13
SP GO:0044429 mitochondrial part 771.00 37.00 9.47 5.4E-13
SP GO:1990204 oxidoreductase complex 78.00 13.00 0.96 9.9E-12
SP GO:0005759 mitochondrial matrix 314.00 22.00 3.86 3.9E-11
SP GO:0043230 extracellular organelle 2385.00 62.00 29.30 1.3E-9
SP GO:0065010 extracellular membrane-bounded organelle 2385.00 62.00 29.30 1.3E-9
SP GO:0070062 extracellular vesicular exosome 2385.00 62.00 29.30 1.3E-9
SP GO:0005740 mitochondrial envelope 586.00 27.00 7.20 2.7E-9
TT GO:0000795 synaptonemal complex 31.00 4.00 0.29 1.9E-4
TT GO:0071944 cell periphery 3877.00 54.00 36.35 5.9E-4
TT GO:0005886 plasma membrane 3800.00 51.00 35.62 2.2E-3
TT GO:0000794 condensed nuclear chromosome 74.00 4.00 0.69 5.1E-3
TT GO:0043186 P granule 13.00 2.00 0.12 6.3E-3
TT GO:0045495 pole plasm 13.00 2.00 0.12 6.3E-3
TT GO:0060293 germ plasm 13.00 2.00 0.12 6.3E-3
TT GO:0009986 cell surface 604.00 12.00 5.66 1.1E-2
TT GO:0030027 lamellipodium 150.00 5.00 1.41 1.3E-2
TT GO:0032420 stereocilium 25.00 2.00 0.23 2.273E-2
Table 3: Enriched Cellular Comparments in Tissues
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Chapter 1 Supplementary Table 2
Figure 1: Novel Transcript Information. Various Information on 8 novel coding tran-
scripts are provided including average expression value, transcript length, CDS length,
ORF length, transcript sequence, cds sequence, ORF sequence, primers used, and expected
amplicon sizes
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Below is the stan code that was used in MAGE.
1 d a t a {
2 / / N’ s
3 i n t <l ower =1> N; / / Number o f o b s e r v a t i o n s
4 i n t <l ower =1> N dpi ; / / Number o f day p o s t i n f e c t i o n t y p e
5 i n t <l ower =1> N t i s s u e ; / / Number o f t i s s u e t y p e s
6 i n t <l ower =1> N be ta ; / / Number o f t i s s u e x d p i i n t e r a c t i o n t e r m s
7
8 / / P r e d i c t o r s
9 i n t o b s t o d p i i n d e x [N ] ;
10 i n t o b s t o t i s s u e i n d e x [N ] ;
11 i n t o b s t o i n t e r a c t i o n i n d e x [N ] ;
12
13 / / Response v a r i a b l e and o f f s e t te rm
14 i n t y [N ] ; / / c o u n t s
15 v e c t o r [N] o f f s e t t e r m ;
16 }
17
18 p a r a m e t e r s {
19 r e a l m u i n t e r c e p t ;
20
21 r e a l b e t a t i s s u e r a w [ N t i s s u e ] ;
22 r e a l b e t a d p i r a w [ N dpi ] ;
23 r e a l b e t a i n t e r a c t i o n r a w [ N dpi * N t i s s u e ] ;
24
25 / / P r e c i s i o n ( i n v e r s e d i s p e r s i o n ) p a r a m e t e r
26 r e a l <l ower =0> p h i ;
27
28 / / h y p e r p r i o r
29 r e a l mu dpi ;
30 r e a l <l ower =0> s i g m a d p i ;
31
32 / / t i s s u e
33 r e a l m u t i s s u e ;
34 r e a l <l ower =0> s i g m a t i s s u e ;
35
36 / / i n t e r a c t i o n
37 r e a l m u i n t e r a c t i o n ;
38 r e a l <l ower =0> s i g m a i n t e r a c t i o n ;
39 }
40 t r a n s f o r m e d p a r a m e t e r s {
41 r e a l b e t a d p i [ N dpi ] ;
42 r e a l b e t a t i s s u e [ N t i s s u e ] ;
43 r e a l b e t a i n t e r a c t i o n [ N dpi * N t i s s u e ] ;
44 / / Combine a l l
45 f o r ( n i n 1 :N ) {
46 b e t a d p i [ o b s t o d p i i n d e x [ n ] ] = 5* mu dpi + s i g m a d p i * b e t a d p i r a w [
o b s t o d p i i n d e x [ n ] ] ;
47 b e t a t i s s u e [ o b s t o t i s s u e i n d e x [ n ] ] = 5* m u t i s s u e + s i g m a t i s s u e *
b e t a t i s s u e r a w [ o b s t o t i s s u e i n d e x [ n ] ] ;
111
48 b e t a i n t e r a c t i o n [ o b s t o i n t e r a c t i o n i n d e x [ n ] ] = 5* m u i n t e r a c t i o n +







54 v e c t o r [N] y h a t ;
55 m u i n t e r c e p t ˜ normal ( 0 , 10) ;
56 / / hype r p r i o r f o r d p i
57 mu dpi ˜ normal ( 0 , 1 ) ;
58 s i g m a d p i ˜ cauchy ( 0 , 2 ) ;
59
60 / / h y e r p r i o r f o r t i s s u e
61 m u t i s s u e ˜ normal ( 0 , 1 ) ;
62 s i g m a t i s s u e ˜ cauchy ( 0 , 2 ) ;
63
64 / / h y e r p r i o r f o r t i s s u e x d p i i n t e r a c t i o n
65 m u i n t e r a c t i o n ˜ normal ( 0 , 1 ) ;
66 s i g m a i n t e r a c t i o n ˜ cauchy ( 0 , 2 ) ;
67
68 / / p r i o r f o r i n v e r s e d i s p e r s i o n
69 p h i ˜ cauchy ( 0 , 2 ) ;
70
71 b e t a t i s s u e r a w ˜ normal ( 0 , 1 ) ;
72 b e t a d p i r a w ˜ normal ( 0 , 1 ) ;
73 b e t a i n t e r a c t i o n r a w ˜ normal ( 0 , 1 ) ;
74
75 f o r ( n i n 1 :N ) {
76 y h a t [ n ] = m u i n t e r c e p t +
77 b e t a d p i [ o b s t o d p i i n d e x [ n ] ] +
78 b e t a t i s s u e [ o b s t o t i s s u e i n d e x [ n ] ] +
79 b e t a i n t e r a c t i o n [ o b s t o i n t e r a c t i o n i n d e x [ n ] ] +
80 l o g ( o f f s e t t e r m [ n ] ) ;
81 }
82 / / l o g l i n e a r n e g a t i v e b i n o m i a l r e g r e s s i o n
83 y ˜ n e g b i n o m i a l 2 l o g ( yha t , p h i ) ;
84 }
85 g e n e r a t e d q u a n t i t i e s {
86 v e c t o r [N] y h a t ;
87 v e c t o r [N] l o g l i k ;
88
89 r e a l d p i 1 i n g l n ;
90 r e a l d p i 3 i n g l n ;
91 r e a l d p i 5 i n g l n ;
92 r e a l d p i 7 i n g l n ;
93 r e a l d p i 9 i n g l n ;
94 r e a l d p i 1 m e s l n ;
95 r e a l d p i 3 m e s l n ;
96 r e a l d p i 5 m e s l n ;
97 r e a l d p i 7 m e s l n ;
98 r e a l d p i 9 m e s l n ;
99 r e a l d p i 1 t b l n ;
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100 r e a l d p i 3 t b l n ;
101 r e a l d p i 5 t b l n ;
102 r e a l d p i 7 t b l n ;
103 r e a l d p i 9 t b l n ;
104 r e a l f c d p i 3 i n g l n ;
105 r e a l f c d p i 5 i n g l n ;
106 r e a l f c d p i 7 i n g l n ;
107 r e a l f c d p i 9 i n g l n ;
108 r e a l f c d p i 3 m e s l n ;
109 r e a l f c d p i 5 m e s l n ;
110 r e a l f c d p i 7 m e s l n ;
111 r e a l f c d p i 9 m e s l n ;
112 r e a l f c d p i 3 t b l n ;
113 r e a l f c d p i 5 t b l n ;
114 r e a l f c d p i 7 t b l n ;
115 r e a l f c d p i 9 t b l n ;
116
117 d p i 1 t b l n = b e t a d p i [ 1 ] + b e t a t i s s u e [ 3 ] + b e t a i n t e r a c t i o n [ 3 ] ;
118 d p i 3 t b l n = b e t a d p i [ 2 ] + b e t a t i s s u e [ 3 ] + b e t a i n t e r a c t i o n [ 6 ] ;
119 d p i 5 t b l n = b e t a d p i [ 3 ] + b e t a t i s s u e [ 3 ] + b e t a i n t e r a c t i o n [ 9 ] ;
120 d p i 7 t b l n = b e t a d p i [ 4 ] + b e t a t i s s u e [ 3 ] + b e t a i n t e r a c t i o n [ 1 2 ] ;
121 d p i 9 t b l n = b e t a d p i [ 5 ] + b e t a t i s s u e [ 3 ] + b e t a i n t e r a c t i o n [ 1 5 ] ;
122
123 d p i 1 m e s l n = b e t a d p i [ 1 ] + b e t a t i s s u e [ 2 ] + b e t a i n t e r a c t i o n [ 2 ] ;
124 d p i 3 m e s l n = b e t a d p i [ 2 ] + b e t a t i s s u e [ 2 ] + b e t a i n t e r a c t i o n [ 5 ] ;
125 d p i 5 m e s l n = b e t a d p i [ 3 ] + b e t a t i s s u e [ 2 ] + b e t a i n t e r a c t i o n [ 8 ] ;
126 d p i 7 m e s l n = b e t a d p i [ 4 ] + b e t a t i s s u e [ 2 ] + b e t a i n t e r a c t i o n [ 1 1 ] ;
127 d p i 9 m e s l n = b e t a d p i [ 5 ] + b e t a t i s s u e [ 2 ] + b e t a i n t e r a c t i o n [ 1 4 ] ;
128
129 d p i 1 i n g l n = b e t a d p i [ 1 ] + b e t a t i s s u e [ 1 ] + b e t a i n t e r a c t i o n [ 1 ] ;
130 d p i 3 i n g l n = b e t a d p i [ 2 ] + b e t a t i s s u e [ 1 ] + b e t a i n t e r a c t i o n [ 4 ] ;
131 d p i 5 i n g l n = b e t a d p i [ 3 ] + b e t a t i s s u e [ 1 ] + b e t a i n t e r a c t i o n [ 7 ] ;
132 d p i 7 i n g l n = b e t a d p i [ 4 ] + b e t a t i s s u e [ 1 ] + b e t a i n t e r a c t i o n [ 1 0 ] ;
133 d p i 9 i n g l n = b e t a d p i [ 5 ] + b e t a t i s s u e [ 1 ] + b e t a i n t e r a c t i o n [ 1 3 ] ;
134
135 / / f o l d change
136 f c d p i 3 t b l n = ( d p i 3 t b l n − d p i 1 t b l n ) / l o g ( 2 ) ;
137 f c d p i 5 t b l n = ( d p i 5 t b l n − d p i 1 t b l n ) / l o g ( 2 ) ;
138 f c d p i 7 t b l n = ( d p i 7 t b l n − d p i 1 t b l n ) / l o g ( 2 ) ;
139 f c d p i 9 t b l n = ( d p i 9 t b l n − d p i 1 t b l n ) / l o g ( 2 ) ;
140
141 f c d p i 3 m e s l n = ( d p i 3 m e s l n − d p i 1 m e s l n ) / l o g ( 2 ) ;
142 f c d p i 5 m e s l n = ( d p i 5 m e s l n − d p i 1 m e s l n ) / l o g ( 2 ) ;
143 f c d p i 7 m e s l n = ( d p i 7 m e s l n − d p i 1 m e s l n ) / l o g ( 2 ) ;
144 f c d p i 9 m e s l n = ( d p i 9 m e s l n − d p i 1 m e s l n ) / l o g ( 2 ) ;
145
146 f c d p i 3 i n g l n = ( d p i 3 i n g l n − d p i 1 i n g l n ) / l o g ( 2 ) ;
147 f c d p i 5 i n g l n = ( d p i 5 i n g l n − d p i 1 i n g l n ) / l o g ( 2 ) ;
148 f c d p i 7 i n g l n = ( d p i 7 i n g l n − d p i 1 i n g l n ) / l o g ( 2 ) ;
149 f c d p i 9 i n g l n = ( d p i 9 i n g l n − d p i 1 i n g l n ) / l o g ( 2 ) ;
150
151 f o r ( n i n 1 :N) {
152 y h a t [ n ] = m u i n t e r c e p t +
153 b e t a d p i [ o b s t o d p i i n d e x [ n ] ] +
113
154 b e t a t i s s u e [ o b s t o t i s s u e i n d e x [ n ] ] +
155 b e t a i n t e r a c t i o n [ o b s t o i n t e r a c t i o n i n d e x [ n ] ] +
156 l o g ( o f f s e t t e r m [ n ] ) ;
157 / / p r e f e r r e d S tan s y n t a x as o f v e r s i o n 2 . 1 0 . 0




Code to Generate Synthetic Data
1 l i b r a r y ( t i d y v e r s e )
2
3 rgampoi s p r o p o s e d <− f u n c t i o n ( n , mu , p r e c i s i o n ) {
4 prob <− p r e c i s i o n / ( p r e c i s i o n + mu)
5 # t h i s d e f i n i t i o n i s d i r e c t l y c o p i e d o f f o f t h e d o c u m e n t a t i o n o f
rnbionom :
6 # ” . . . An a l t e r n a t i v e p a r a m e t r i z a t i o n ( o f t e n used i n e c o l o g y ) i s
7 # by t h e mean mu ( s e e above ) , and s i z e , t h e d i s p e r s i o n p a r a m e t e r ,
8 # where prob = s i z e / ( s i z e +mu) . The v a r i a n c e i s mu + muˆ2 / s i z e i n t h i s
p a r a m e t r i z a t i o n . . . . ”
9




14 # ’ S i m u l a t e t h e RNA seq samples f o r a gene i n two c o n d i t i o n s
15 # ’
16 # ’ @param n Number o f r e p l i c a t e s t o make
17 # ’ @param e x p r s Mean E x p r e s s i o n s
18 # ’ @param f c Fold change
19 # ’ @param d i s p e r s D i s p e r s i o n
20 # ’
21 # ’ @return
22 # ’ @export
23 # ’
24 # ’ @examples
25 s i m u l a t e <− f u n c t i o n ( n , expr s , fc , d i s p e r s ) {
26 s1 <−
27 rgampoi s p r o p o s e d ( n = n ,
28 mu = exprs ,
29 p r e c i s i o n = 1 / d i s p e r s )
30
31 # m u l t i p l y f o l d change f o r t h e second group
32 s2 <−
33 rgampoi s p r o p o s e d ( n = n ,
34 mu = e x p r s * fc ,
35 p r e c i s i o n = 1 / d i s p e r s )
36
37 l i s t ( r e p = seq ( 1 , n ) ,
38 s1 = s1 ,
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39 s2 = s2 )
40 }
41
42 # ’ Th i s f u n c t i o n d e t e r m i n e s what % of t h e d a t a i s DEG
43 a d j u s t meta <− f u n c t i o n ( meta , PERC = 0 . 1 ) {
44 s p l i t d f <− base : : s p l i t ( meta , meta $ f c )
45 name s p l i t d f <− names ( s p l i t d f )
46 t o sample <− s e t d i f f ( name s p l i t df , ” 1 ” )
47 r e s <− l i s t ( )
48 f o r ( sample name i n t o sample ) {
49 sampled df <−
50 d p l y r : : sample n ( s p l i t d f [ [ sample name ] ] , ba se : :NROW( s p l i t d f [ [ ” 1 ”
] ] ) * PERC /
51 l e n g t h ( t o sample ) )
52 r e s [ [ sample name ] ] <− sampled df
53 }
54




59 # S i m u l a t e t h e RNA−seq d a t a
60 # P a r a m e t e r s −−−−
61 e x p r s <−
62 seq ( 1 0 , 1000 , by = 5)
63 d i s p e r s <− seq ( 0 . 5 , 2 , by = 0 . 1 ) # d i s p e r s i o n
64 f c <− c ( 1 , 2 , 0 . 5 ) # f o l d change
65
66
67 # S i m u l a t e t h e RNA−seq d a t a
68 s i m u l a t e wi th n <− f u n c t i o n (N REP , meta , PREFIX ) {
69 d a t a sim tmp <− meta %>%
70 mu ta t e ( sample = pmap ( l i s t ( n = N REP , expr s , fc , d i s p e r s ) , s i m u l a t e ) )
71
72 d a t a sim <− d a t a sim tmp %>%
73 mu ta t e ( sample = map ( sample , a s t i b b l e ) ) %>%
74 u n n e s t ( ) %>%
75 g a t h e r ( sample , da t a , 5 : 6 ) %>%
76 mu ta t e ( t a r g e t i d = p a s t e 0 ( ” r ” , expr s , ” f c ” , fc , ” d ” , d i s p e r s ) ) %>%
77 mu ta t e ( i d = p a s t e 0 ( sample , ” ” , r e p ) )
78
79 DEPTH <− FALSE
80 i f (DEPTH) {
81 sim meta <− d a t a sim %>%
82 d i s t i n c t ( i d ) %>%
83 mu ta t e ( s i z e f a c t o r = rnorm (
84 n = NROW( . ) ,
85 mean = 1 ,
86 sd = 0 . 1
87 ) ) %>%
88 mu ta t e ( d e p t h = 1 e7 * s i z e f a c t o r )
89
90 d a t a sim <− d a t a sim %>%
91 mu ta t e ( d a t a = d a t a / 1 e7 ) %>%
115
92 l e f t j o i n ( sim meta , by = ” i d ” ) %>%
93 mu ta t e ( d a t a = as . i n t e g e r ( d a t a * d e p t h ) )
94 }
95
96 # G e n e r a t e wide m a t r i x
97 d a t a sim w <− d a t a sim %>%
98 s e l e c t ( t a r g e t id , id , d a t a ) %>%
99 s p r e a d ( id , d a t a )
100
101 cname <− co lnames ( d a t a sim w) [−1]
102
103 # Save wide e x p r e s s i o n d a t a −−−−
104 w r i t e t s v ( d a t a sim w,
105 p a s t e 0 ( PREFIX , N REP , ” . t s v ” ) )
106
107 i n v i s i b l e ( l i s t ( d a t a sim w, meta , meta sample ) )
108 }
109
110 s i m u l a t e a l l <− f u n c t i o n ( meta , SET , PERC , NREP) {
111 #SET <− 1
112 #PERC <− 0 . 1
113 meta a d j <− a d j u s t meta ( meta , PERC = PERC)
114 s e t . s eed ( a s . i n t e g e r (20 * SET ) )
115 d a t a <−
116 s i m u l a t e wi th n (
117 NREP,
118 meta ad j ,
119 PREFIX = p a s t e 0 (
120 ” t e s t s / benchmark d a t a / S” ,
121 SET ,








130 # C o n s t r u c t m u l t i p l e s c e n a r i o s −−−−
131 meta <− as t i b b l e ( expand . g r i d (
132 e x p r s = exprs ,
133 f c = fc ,
134 d i s p e r s = d i s p e r s
135 ) )
136
137 SETS <− seq ( 1 , 3 )
138 PERCS <− c ( 0 . 0 1 , 0 . 1 , 0 . 5 )
139 NREPS <− c ( 3 , 10 , 50)
140 sim param t a b l e <− expand . g r i d ( s e t s = SETS ,
141 p e r c s = PERCS ,
142 n r e p s = NREPS) %>%
143 as t i b b l e
116
Workflow used for Benchmark
1 df t o edg <− f u n c t i o n ( d f ) {
2 / / c o n v e r t s d a t a f rame t o e x p r e s s i o n m a t r i x wi th gene names i n rownames
and
3 exp mat <− df t o e x p r e s s i o n m a t r i x ( d f )
4
5 # i n s t a n t i a t i o n
6 dge <− edgeR : : DGEList ( c o u n t s = exp mat )
7
8 # n o r m a l i z a t i o n
9 dge <− edgeR : : c a l c N o r m F a c t o r s ( dge , method = ”TMM” )
10
11 # e s t i m a t i o n
12 dge <− edgeR : : estimateGLMCommonDisp ( dge )
13 dge <− edgeR : : es t imateGLMTrendedDisp ( dge )





19 dge e d g e r <− df t o edg ( d f )
20 mod <− model . m a t r i x ( ˜ s i d , d a t a = meta sample )
21 dge f i t <− edgeR : : g l m F i t ( dge edger , mod )
22 dge l r t <− edgeR : : glmLRT ( dge f i t , c o e f = ” s i d s 2 ” )
23 r e s e d g e r <− dge l r t $ t a b l e
1 / / S t an model used i n benchmark
2 d a t a {
3 / / N’ s
4 i n t <l ower =1> N; / / Number o f o b s e r v a t i o n s
5 i n t <l ower =1> N f a c t o r ; / / Number o f day p o s t i n f e c t i o n t y p e
6
7 / / C o v a r i a t e and r e p o n s e
8 i n t i d x b [N ] ;
9
10 i n t y [N ] ; / / c o u n t s
11 v e c t o r [N] d e p t h ;
12 }
13
14 p a r a m e t e r s {
15 r e a l a l p h a ; / / i n t e r c e p t
16 r e a l b e t a r a w [ N f a c t o r ] ; / / random e f f e c t
17 r e a l <l ower =0> p h i ; / / 1 / d i s p e r s i o n
18
19 r e a l mu beta ; / / h y p e r p r i o r mean
20 r e a l <l ower =0> s i g m a b e t a ; / / h y p e r p r o r s t d
21
22 }
23 t r a n s f o r m e d p a r a m e t e r s {
24 r e a l b e t a [ N f a c t o r ] ;
25
26 f o r ( n i n 1 :N ) {






32 v e c t o r [N] y h a t ;
33
34 / / Hyperparms
35 mu beta ˜ normal ( 0 , 1 ) ;
36 s i g m a b e t a ˜ cauchy ( 0 , 2 ) ;
37
38 a l p h a ˜ normal ( 0 , 10) ;
39 b e t a r a w ˜ normal ( 0 , 1 ) ;
40
41 / / p r i o r f o r i n v e r s e d i s p e r s i o n
42 p h i ˜ cauchy ( 0 , 2 ) ;
43
44
45 f o r ( n i n 1 :N ) {
46 y h a t [ n ] = a l p h a +
47 b e t a [ i d x b [ n ] ] +
48 l o g ( d e p t h [ n ] ) ;
49 }
50 / / l o g l i n e a r n e g a t i v e b i n o m i a l r e g r e s s i o n
51 y ˜ n e g b i n o m i a l 2 l o g ( yha t , p h i ) ;
52 }
53 g e n e r a t e d q u a n t i t i e s {
54 v e c t o r [N] y h a t ;
55 v e c t o r [N] l o g l i k ;
56
57 f o r ( n i n 1 :N) {
58 y h a t [ n ] = a l p h a +
59 b e t a [ i d x b [ n ] ] +
60 l o g ( d e p t h [ n ] ) ;
61 / / p r e f e r r e d S tan s y n t a x as o f v e r s i o n 2 . 1 0 . 0






In Figure 2, PCA based on sample-wise TPM as features is performed. This demonstrates
that using the TPM or raw counts in PCA may not clearly show the global pattern that was
shown with log2FC due to the heterogeneity that exists among tissues at the baseline.
Figure 2: Principal Component Analysis using raw TPM.
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Mapper Parameter Selection
Figure 3: Tuning Mapper Parameters. Multiple networks can be generated based on the
two parameters, resolution and gain. The first panel shows the grid of networks generated
based on the set of specific parameters. The second panel shows the corresponding dunn
index for a network.
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